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1 SUMMARY 
Cell division cycle 42 (Cdc42) is a member of the Rho GTPase family and has 
pivotal functions in actin organization, cell migration and proliferation. 
Furthermore, Cdc42 has been shown to regulate dendritic cell (DC) functions 
critical for the initiation and control of immune responses. For example, there is 
evidence that Cdc42 plays a role in antigen uptake, migration and the control of T 
cell stimulation. However, as constraints for most of these studies, Cdc42 has been 
studied using dominant negative and constitutively active mutants with possible 
unspecific effects on other members of the Rho GTPase family like Rac1 and 
RhoA. Thus, the actual contribution of Cdc42 to these processes might not have 
been fully addressed. Here we used a LoxP/Cre-recombinase approach to knock 
out Cdc42 selectively in DCs. Using bone-marrow derived dendritic cells (BMDCs) 
we confirm that Cdc42 contributes to antigen uptake and the presentation of 
whole protein antigen. Furthermore, we demonstrate that pre-processed antigenic 
peptides are inefficiently presented by Cdc42-ko DCs, as Cdc42 regulates 
intracellular levels of lysosomal proteases required for invariant chain (Ii) 
processing and thus, specifically MHC II loading. As a result, Ii was not efficiently 
degraded in Cdc42-ko BMDCs and accumulated on the surface of these cells in an 
actin-dependent manner, possibly as a result of misrouting of lysosomal contents 
into culture supernatants. Our results propose that Cdc42 controls an actin-
dependent mechanism, which regulates MHC II loading, antigen presentation and 
thus, DC-mediated immunity.     
This study is important for understanding basic mechanisms in DCs required for 
the initiation of adaptive immune responses. Cdc42 is required for efficient 
antigen presentation and therefore crucial to efficiently eliminate pathogens. 
Understanding how Cdc42 contributes to antigen presentation might lead to new 
therapeutic strategies to manipulate DC function in fighting infections, diseases 
and tumors. 
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2 ZUSAMMENFASSUNG 
Cell Division Cycle 42 (engl., Cdc42) reguliert die Polymerisierung von Aktin, die 
Migration und die Proliferation von Zellen. In dendritischen Zellen reguliert 
Cdc42 unter Anderem die Aufnahme von Antigenen, deren Transport von der 
Peripherie zu drainierenden lymphatischen Organen, sowie die T Zell-
Aktivierung. Dadurch spielt Cdc42 ein wichtige Rolle bei der Initiierung und 
Kontrolle von Immunantworten.  
In vorangegangenen Arbeiten wurde Cdc42 vornehmlich unter Zuhilfenahme von 
Proteinmutanten studiert, die in der Zelle eine Aktivierung von Cdc42 
unterdrückten oder konstitutiv aktiv vorlagen. Da diese Mutanten möglicherweise 
nicht ausschließlich Cdc42, sondern auch andere Rho GTPasen, wie z.B. Rac1 und 
RhoA beeinflussen, entschieden wir uns für einen spezifischen knockout, der ein 
Fehlen von Cdc42 in dendritischen Zellen verursacht.  
Unter Verwendung von Cdc42-defizienten aus dem Knochenmark differenzierten 
dendritischen Zellen, konnten wir in vitro zeigen, dass Cdc42 sowohl bei der 
Aufnahme von Antigenen, als auch bei deren Präsentation zu CD4+ und CD8+ 
T Zellen eine Rolle spielt. Interessanterweise war in Cdc42-/--dendritischen Zellen 
auch die MHC Klasse II-abhängige Präsentation von bereits prozessierten 
Peptiden vermindert, als Folge einer Fehlsortierung der für die Beladung von 
MHC Klasse II benötigten lysosomalen Proteasen: Cdc42-defiziente dendritische 
Zellen zeigten eine unvollständige Prozessierung der Ia antigen-associated invariant 
chain (engl., Ii) von MHC Klasse II, wodurch der Austausch von Antigenen auf 
MHC Klasse II nicht effizient stattfinden kann. Ii gebundene MHC Klasse II 
Moleküle akkumulierten somit in einem Aktin-abhängigen Mechanismus an der 
Zelloberfläche von Cdc42-defizienten dendritischen Zellen- mit Auswirkungen 
auf die Beladung und somit die MHC Klasse II-abhängige Präsentation von 
Antigenen und somit die Effizienz der Immunantwort.  
Diese Ergebnisse zeigen, dass Cdc42 benötigt wird, um auf exogene Antigene zu 
reagieren und eine effiziente adaptive Immunantwort einzuleiten. Somit ist Cdc42 
möglicherweise notwendig um Pathogene effizient zu bekämpfen. Cdc42-
regulierte Prozesse könnten demnach von essentieller Bedeutung für die 
Bekämpfung von Infektionen, Krankheiten und auch Tumore durch dendritische 
Zellen sein. 
   INTRODUCTION 
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3 INTRODUCTION 
3.1 Dendritic cells as antigen presenting cells 
3.1.1 DCs – sentinels of the immune system 
Dendritic cells (DCs) are professional antigen presenting cells (APC) with pivotal 
roles for the induction of both adaptive and innate immune responses. Their 
competence is based primarily on their ability to capture and present antigens to 
T cells, thereby regulating T cell functions in immunity and tolerance (reviewed in 
(1-3)). Depending on the nature of environmental stimuli, DCs “decide” between 
triggering immunity by stimulating immunogenic T cells and NK cells, and 
tolerance by inducing deletion, anergy or regulatory T cell (Treg) differentiation.  
 
DCs originate from a common myeloid precursor (CMP) in the bone marrow that 
becomes committed to the DC lineage upon encountering a combination of the 
cytokines granulocyte-macrophage colony stimulating factor (GM-CSF), 
macrophage colony stimulating factor (M-CSF), Flt3 Ligand (Flt3L) and 
transforming growth factor beta (TGF-β1) (reviewed in (4)). This common DC 
precursor (CDP) gives rise to precursors of conventional DCs (cDCs) termed pre-
DCs and plasmacytoid DCs (pDCs) in the bone marrow. Both, pre-DCs and pDCs 
leave the bone marrow, enter the blood stream and seed lymphoid organs such as 
spleen, lymph nodes and Peyer’s patches, where they differentiate into one of the 
multiple DC subsets (5-7), based on the tissue-specific expression of cytokines and 
transcription factors. Whereas cDCs are very effective in antigen capture and 
presentation, pDCs have a limited potential to present extracellular tissue antigens 
and function mainly in producing large amounts of type I interferons in response 
to viruses (reviewed in (8)). However, most DCs share a high expression of the 
integrin CD11c, but may differ in expression levels of major histocompatibility 
complex (MHC) II or co-stimulatory molecules CD80 and CD86. 
 
DCs comprise multiple subsets with distinct localizations throughout the body (9), 
sampling the environment for both self and foreign antigens whilst developing 
functional specifications due to environmental stimuli, such as cytokines. Tissue-
resident DCs enter lymphoid tissues as pre-DCs released from the bone marrow 
and differentiate inside the tissues. Migratory DC subsets localized in peripheral 
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non-lymphoid tissues act as sentinels of the immune system and migrate 
directionally via the lymphatic vessels into the T cell area of lymph nodes to 
initiate immune responses (10, 11). Tissue-resident DCs, on the other hand, 
acquire antigens from migratory DCs, or by sampling blood or lymph and are key 
players in producing cytokines and priming T cells (12).  
 
Half of the DCs present in lymph nodes are resident DCs, the other half migratory 
DCs that, in the absence of infection, migrate spontaneously through the 
lymphatic vessels. Depending on the local distribution, lymph nodes drain 
different organs and tissues and therefore contain specialized migratory DC 
subsets. For example, cutaneous lymph nodes drain the skin and therefore include 
migratory DC subsets such as Langerhans cells (CD11c+MHC II+ expressing 
Langerin and EpCam) residing in the epidermis, Langerin+ dermal DCs 
(MHC II+CD103+Langerin+) or Langerin- dermal DCs (MHC II+CD103-Langerin-), 
the latter two both residing in the dermis of the skin (13). Mesenteric lymph nodes 
(MLN), on the other hand, drain the gut and contain migratory DC subsets 
originating from the lamina propria that can be characterized based on the 
expression of CD11b and CD103 (CD11c+MHC II+CD103+CD11b- or CD11b+ DCs) 
(14). 
 
Mouse spleens, as opposed to lymph nodes, are exclusively comprised of blood-
derived, resident DCs. Splenic DCs subsets can be distinguished based on the 
expression of CD4 and CD8α (CD4+ and CD8+ DCs and double-negative DCs) and 
have distinct, cell type-specific functions. Depending on the nature of antigen 
specific pathways of entry are triggered in these splenic DC subsets that lead to 
the induction of CD8+ or CD4+ T cell responses. The induction of CD8+ T cell 
responses involves the presentation of exogenously derived antigens on MHC I 
molecules, a process termed cross-presentation (reviewed in (15)). CD4+ T cell 
responses, on the other hand, require the presentation of exogenously derived 
antigens in the context of MHC II (reviewed in (12)).  
3.1.2 DC maturation  
DCs residing in tissues are of an immature phenotype expressing low amounts of 
surface MHC I, MHC II and costimulatory molecules (e.g. CD86) and have a high 
potential to take up antigen. However, upon migration to draining lymph nodes 
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DCs mature and develop their full potential to activate T cells. DC maturation is a 
signaling switch typically turned on upon microbial or viral-derived external 
stimuli, such as lipopolysaccharide (LPS), CpG DNA or dsRNA (16). However, 
DC maturation can also be triggered by pro-inflammatory cytokines, such as 
tumor necrosis factor alpha (TNFα) and interkeukin 1 beta (IL-1β) or ligation of 
CD40 and a variety of noninflammatory, pathogen-unrelated stimuli (16, 17). 
 
Besides triggering both nuclear factor kappaB (NF-κB) activation and the 
production of pro-inflammatory cytokines, the “activation” of DCs leads to 
substantial changes of cell shape, mediated by rearrangements of the actin 
cytoskeleton. These changes include a shut down of the cell’s potential to take up 
antigens via macropinocytosis, pinocytosis and receptor-mediated endocytosis. 
However, a recent publication challenged the belief that all mechanisms of 
endocytosis are affected upon DC maturation by showing that uptake via the 
CD205 receptor (DEC-205) was still functional in LPS-treated, mature BMDCs (18).  
DC maturation also includes the transport of antigen-loaded MHC I as well as 
MHC II molecules to the cell surface for recognition by T cells (17) (reviewed in 
(16)). MHC II antigen presentation in mature DCs is accompanied by a 
downregulation of transcription of the transcriptional coactivator of MHC II 
genes, the MHC class II transactivator (CIITA). Additionally, the formation of 
MHC II-peptide complexes in lysosomal compartments is downregulated due to a 
decreased endosomal pH within the endocytic system, as a result of an increased 
assembly of a proton pump (for references, see (6)). MHC II-peptide complexes are 
translocated to the plasma membrane and cell surface MHC II, which is constantly 
recycling on immature DCs, is stabilized at the plasma membrane as a result of 
decreased ubiquitination of the MHC II β chain (19).  
 
Besides the regulation of MHC expression, DC maturation also includes the 
upregulation of B7 family members on DCs, which include CD80 and CD86 and 
provide co-stimulation. Additionally, DCs produce and secrete pro-inflammatory 
cytokines such as IL12 and interferon alpha (IFNα) that constitute additional 
signals to prime T cells (2). All these processes contribute to fully enable DCs as 
potent inducers of adaptive immune responses. 
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3.1.3 DC antigen presentation 
DCs are capable of different strategies to present self- and foreign antigens to 
T cells, thereby inducing tolerogenic or immunogenic immune responses. 
Endogenous antigens are loaded onto MHC I molecules, whereas exogenously 
derived antigens are presented by the classical MHC II antigen pathway. Besides 
these two “classical” antigen presentation pathways two “non-classical” pathways 
also exist, which include the presentation of exogenously derived antigens on 
MHC I molecules (cross-presentation) (20) and autophagy of cytosolic components 
for presentation on MHC II (21). 
In order to present exogenously derived antigens, DCs need to take up, process 
and load these antigens onto MHC I as well as MHC II molecules. This chapter’s 
focus will be on the mechanisms involved in MHC I- or MHC II-dependent 
presentation of exogenously derived antigens by DCs contributing to an adaptive, 
immunogenic immune response. 
3.1.3.1 Uptake of soluble and particulate antigens 
Immature DCs constitutively sample their environment using three major routes 
of antigen uptake: clathrin-independent endocytosis (CIE), clathrin-dependent 
endocytosis (CDE) and phagocytosis. Whereas CIE and CDE are mechanisms 
required for fluid-phase uptake, phagocytosis mediates the uptake of large 
particulate antigens, e.g. dead cells.  All pathways of antigen entry into cells are 
 
Figure 1: Pathways of entry into cells. 
CLIC, tubular intermediates of clathrin and dynamin-independent carriers; GEEC, glycosyl 
phosphatidylinositol-anchored protein enriched early endosomal compartments. Figure from 
Mayor & Pagano, 2007 (22). 
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summarized in Figure 1 (figure from (22), also reviewed in (23)). For this study 
relevant pathways will be described in the following section. 
 
Uptake of soluble antigens 
Both CDE and CIE constitute mechanisms for fluid-phase entry into cells. The 
latter includes macropinocytosis, pinocytosis and mechanisms dependent or 
independent of caveolin and/or dynamin (summarized in Figure 1). 
 
The majority of soluble antigens are taken up by clathrin-independent 
macropinocytosis, a mechanism during which DCs form protrusions, thereby 
engulfing large amounts of the fluid phase. This process is highly actin-
dependent: active actin polymerization at the site of entry is required to 
mechanically push the plasma membrane. Macropinocytosis is constitutively 
active in immature DCs and is shut down upon DC activation. However, this 
uptake mechanism is rather unspecific and results in the acquisition of large 
volumes of surrounding fluid. A variation of this process, pinocytosis allows for 
small volume fluid-phase uptake. A prominent example for macropinocytosis is 
ovalbumin (OVA) uptake by DCs, a model antigen, which does not trigger a 
specific pathway of entry. 
 
DCs can also capture antigens through receptor-engagement followed by the 
internalization of these receptor-bound antigens (reviewed in (24)). Depending on 
the receptor triggered, this process can be either clathrin-dependent or clathrin-
independent; the latter constitutes a minor route for some selective receptors 
including Wnt and Notch receptors (reviewed in (25)). However, CDE is the major 
pathway, by which receptor-engaged antigens are internalized. After formation of 
a clathrin coat surrounding parts of the plasma membrane, receptors are 
sequestered into these structures and then trigger the recruitment of accessory 
proteins required for membrane bending, vesicle formation and vesicle budding. 
Proteins involved in CDE include plasma-membrane deforming F-Bar proteins 
(FCHo), actin-nucleating proteins (e.g. neutral Wiskott-Aldrich syndrome protein 
(N-WASP)), proteins that connect the emerging vesicle with the pre-existing actin 
lattice (e.g. Huntingtin interacting protein 1 related (Hip1r)) and finally proteins 
that actively nucleate actin filaments (e.g. the actin related protein-2/3 (Arp2/3) 
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complex and cell division cycle 42 protein (Cdc42)) to mechanically separate the 
vesicle from the plasma membrane (26). 
Interestingly, clathrin-mediated vesicle budding also takes place at the trans-Golgi 
network (TGN), where it serves to supply the endosomal system with lysosomal 
proteases in a mannose-6-phosphate receptor (46kDa M6pr)- and actin-dependent 
manner. M6pr-mediated clathrin-dependent vesicle budding is required for 
antigen presentation, since it constitutes the major route of protease exit from the 
TGN (27). Lysosomal proteases that travel in an M6pr-dependent manner are for 
example cathepsins, required for the processing of antigens as well as MHC II 
maturation, as described in chapter 3.1.3.3.  
 
Uptake of particles and cells 
DCs are not only capable of fluid-phase uptake, but can also take up of large 
particles (>0.5 µm), such as dead or dying cells, environmental debris or 
pathogenic bacteria. This process is termed phagocytosis and includes an 
extensive reshaping of the plasma membrane and active actin polymerization at 
sites of entry. Phagocytosis can either be FC-receptor-mediated (here the cell 
“reaches” for particles by forming protrusions) or complement-mediated (here 
particles “sink” into cells) and may also take place inside the cell (autophagy) to 
engulf cytosolic material, organelles and microorganisms (all reviewed in (28)). In 
adaptive immunity, DC phagocytosis is important for the acquisition of bacterial 
antigens that are presented to immunogenic T cells required for pathogen 
clearance. Receptor engagement triggered by bacteria induces the production of 
pro-inflammatory cytokines and chemokines that direct adaptive immunity 
towards local and systemic responses.  
3.1.3.2 Antigen cross-presentation 
As opposed to classical, direct MHC I presentation of endogenous antigens, 
antigen cross-presentation provides the presentation of exogenously derived 
antigens in the context of MHC I, which may include immune complexes, bacteria, 
parasites as well as cellular antigens. Antigen-loaded MHC I complexes are 
recognized by naïve CD8+ T cells, contributing to activation, expansion and 
differentiation of these T cells into effectors including cytotoxic T lymphocytes 
(CTL). CTL are capable of destroying virus-infected cells, tumor cells or APCs 
infected with intracellular parasites. The term cross-priming refers to antigen cross 
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over from a donor cell to the host APC, which then initiates MHC I-restricted CTL 
priming.  
The mechanism of antigen cross-presentation has been extensively reviewed (20, 
29, 30). In brief, antigens are internalized into specialized compartments dedicated 
to the generation of MHC I restricted peptides. These compartments can be 
phagosome-endoplasmic reticulum (ER) hybrid compartments (for references, see 
(20)) and generally feature a basal pH. In these compartments, endocytosed 
proteins are either proteolytically degraded, or exported to the cytosol for 
degradation by the proteasome, followed by transporter associated with antigen 
presentation (TAP)-dependent re-import into the vesicle. The peptides are loaded 
onto either newly synthesized MHC I molecules originating from the ER, or 
recycling MHC I complexes re-internalized from the plasma membrane, followed 
by transport of peptide-loaded MHC I complexes to the cell surface. 
3.1.3.3 MHC II antigen presentation: A role for invariant chain 
Apart from cross-presentation, DCs use a mechanism termed MHC II antigen 
presentation to present exogenously derived antigens in the context of MHC II to 
CD4+ T cells.  
Figure 2 summarizes the basic pathway of MHC II loading (from (31)). In brief, a 
trimer of MHC II α- and β-chains assembles in the ER with the assistance of three 
 
Figure 2: The basic MHC class II 
antigen presentation pathway.  
For description, see text. ER, 
endoplasmic reticulum; APC, 
antigen-presenting cell; MIIC, 
MHC II loading compartment; 
TCR, T cell receptor; Ii, invariant 
chain. Figure from Neefjes et al., 
2011 (31). 
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invariant chain (Ii) molecules. This Ii-MHC II heterotrimer travels though the 
Golgi to the MHC class II loading compartment (MIIC), a process mediated by two 
dileucine sorting motifs in the N-terminal of Ii (32-34). Ii-MHC II is transported 
either directly to the MIIC, or via the plasma membrane followed by rapid re-
internalization. Along the endocytic route, Ii is processed until only the class II-
associated Ii peptide (CLIP) occupies the MHC II binding groove, which in the 
MIIC can be exchanged for the antigenic peptide by the chaperone H2-M (HLA-
DM in humans). Ii processing proceeds from C-terminal to N-terminal direction, 
giving rise to degradation intermediates of different sizes that will be introduced 
in chapter 5.3.2 in more detail. “Mature”, peptide-loaded MHC II molecules are 
then transported from the MIIC to the plasma membrane, where peptides are 
presented to CD4+ T cells.  
The soluble, lysosomal proteases cathepsin S (Ctss) and cathepsin L (Ctsl) are key 
players in Ii processing and thus MHC II loading (35-40).  However, activity of 
these two proteases varies between cell types and it may only be noted here that 
Ctss is the major protease in DCs that conducts the final step in Ii degradation.  
 
The nature of lysosomes is important for MHC II antigen presentation, because 
these compartments supply the MIIC with proteases required for Ii as well as 
antigen processing. Supply of lysosomes with soluble proteases such as cathepsins 
is M6pr-dependent (41, 42), whereas lysosomal membrane proteins like lysosome-
associated membrane glycoprotein-1 (LAMP-1) are transported in an M6pr-
independent manner (for a review in lysosome biogenesis, see (27)). However, 
both pathways depend on clathrin-mediated vesicle budding (see chapter 3.1.3.1). 
Cathepsins leave the TGN as precursors and are processed into their mature forms 
upon decreasing pH as they travel along the endocytic route. Endosomal 
acidification depends on the V-ATPase proton pump, which translocates protons 
into the endosomal lumen. M6pr translocate from these acidifying endosomes and 
are recycled back to the TGN. Resulting lysosomes lack M6pr, are rich in 
lysosomal membrane proteins and have a pH below five (43), ready to provide 
their lytic functions.  
3.1.3.4 DC - T cell interaction 
DC-T cell interaction includes the formation of an immunological synapse that 
includes MHC-T cell receptor (TCR) engagement (termed signal 1) in the absence 
or presence of costimulation (termed signal 2). Depending on the type of effector 
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function, DCs deliver an additional signal (termed signal 3), which determines T 
cell differentiation. For example, IL-12 secretion as a third signal promotes either 
TH1-cell or CTL development (2). Which kind of response is triggered, depends on 
the DC’s maturation status regarding the expression of costimulatory molecules 
CD40, CD80 and CD86, and both its ability to form functional cell-cell contacts and 
trigger third signal responses, such as secretion of pro-inflammatory cytokines for 
CTL differentiation. All those mechanisms contribute to the DC’s potential to 
initiate effective immune responses. 
3.2 Small Rho GTPase Cdc42 and its cellular functions 
3.2.1 Small Rho GTPases 
Small guanosine triphosphate-binding proteins (GTPases) are central regulators of 
a variety of local intracellular events. They act as molecular switches cycling 
between an active GTP-bound and inactive GDP-bound state. Nucleotide 
exchange on GTPases is a tightly controlled process that involves different classes 
of proteins: guanine nucleotide exchange factors (GEFs) promote the exchange of 
GDP for GTP from these molecules, GTPase-activating proteins (GAPs) increase 
the intrinsic GTPase activity of their targets, thereby promoting the hydrolysis of 
GTP back to GDP inducing an inactive GDP-bound state, and guanine nucleotide-
dissociation inhibitors (GDIs) that sequester GTPases away from their regulators 
and targets at their membrane sites of action, by masking their prenyl membrane 
binding groups (44). Over 150 GTPases have been identified in humans including 
the Ras, Rab, Arf and Rho family members (45); each member triggering specific 
signaling cascades tightly controlled through the expression of its effectors in the 
respective cell types. 
 
Mammalian Rho GTPases comprise a family of 20 intracellular signaling proteins 
with well-documented functions in regulating the actin cytoskeleton. Active GTP-
bound Rho GTPases target downstream effector proteins triggering signaling 
cascades that lead to the reorganization of the cell’s cytoskeleton with implications 
for vesicle transport, microtubule dynamics, cell polarity and filopodia formation, 
the latter two required for cell migration. The three most prominent and best-
characterized Rho GTPases are Cdc42, Ras-related C3 botulinum toxin substrate 1 
(Rac1) and transforming protein RhoA (RhoA). While Cdc42 and Rac1 trigger 
similar cellular functions using related mechanisms, RhoA often acts as an 
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antagonist for Cdc42 and Rac1 (46). Multiple functions specific for Cdc42, Rac1 or 
RhoA have been ascribed including morphogenesis, polarity, movement, and cell 
division, summarized in a variety of excellent reviews (44, 47-51). 
3.2.2 Constraints in studying Rho GTPases 
Until now, Rho GTPases have mostly been studied using dominant negative (dn) 
and constitutively active (ca) mutants. Dn-mutants bind GEFs, thereby blocking 
their activity required for nucleotide exchange on endogenous GTPase proteins. 
Ca-mutants, on the other hand, are GTP-bound mutants that cannot hydrolyze 
GTP and therefore remain constitutively active. Limitations of these approaches 
rely on the nature of most GEFs targeting more than one Rho GTPase: inactivating 
one GEF could lead to inhibition of more than one Rho GTPase (46). Besides these 
mutants, bacterial toxins have been used to target and thereby inactivate 
endogenous Rho GTPases, unfortunately comprising a similar lack of specificity 
(52). The recent availability of various Rho GTPase knockout mice provides a 
better means to study the functions of selected GTPases in more detail- and also 
provides new insights for their in vivo functions (reviewed by (44, 53). However, a 
global Cdc42 knockout is embryonic lethal (54). 
3.2.3 Cdc42 contributes to actin dynamics 
Small Rho GTPases, especially Cdc42, are active at the cell periphery close to 
membranes, where they promote actin polymerization upon external stimuli. 
Active, GTP-bound Cdc42 has conserved roles in regulating membrane-
deformations of different kinds at the plasma membrane; a prominent example is 
the formation of a lamellipodium at the leading edge of migrating cells. The 
lamellipodium is an area consisting of branched as well as linear, bundled actin 
filaments, which push against the plasma membrane, thereby inducing 
protrusions. Whereas membrane ruffling constitutes a rather mild form of 
membrane deformations, the formation of filopodia in migrating cells requires 
stronger forces in form of actin bundles consisting of linear actin filaments 
connected by cytoskeletal linkers (55).  
GTP-bound Cdc42 stimulates effector proteins that act on the actin cytoskeleton, 
promoting basically either the branching of actin filaments or linear filament 
growth. The branching, as well as the formation of de-novo actin filaments is 
mediated by Cdc42-dependent activation of N-WASP and WASP, which then 
recruit the Arp2/3 complex promoting nucleation and elongation of branched 
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actin networks (56, 57). Arp2/3-dependent actin polymerization contributes to 
membrane ruffling, a process by which a cell builds up membrane tension and 
increases its surface area in order to produce delimited membrane protrusions 
(51). Linear actin polymerization, as opposed to actin branching, requires Cdc42-
signaling via formins (58), which are protein dimers surrounding barbed ends of 
filaments, thereby preventing the recruitment of capping proteins. Both 
mechanisms of Arp2/3-mediated actin branching and the formin-dependent 
linear polymerization of filaments are effects that occur downstream of Cdc42 
signaling. A protein kinase C (PKCα)- and Src kinase-dependent signaling cascade 
upstream of Cdc42 leads to the formation of ring-like cell protrusions mediating 
cell-extracellular matrix interactions called podosomes (59). 
 
Besides contributing to the general shape of cells in the steady state, these 
mechanisms also play critical roles for the reorganization of intracellular contents 
that occur upon extracellular stimuli. Cell polarization for example is a Cdc42-
dependent process (60), in which cells have to asymmetrically reorganize their 
contents in order to react upon certain stimuli. Cell polarity is important for 
asymmetric cell division, directed cell migration, or the directed flow of proteins 
or organelles along microtubules towards a certain location, e.g. the 
immunological synapse. The latter requires microtubule-organizing center 
(MTOC) reorientation, which is highly actin- as well as Cdc42-dependent (61).  
 
Intracellular protein transport in animal cells involves long-range vesicle transport 
along microtubules that originate from the MTOC and point towards the cell 
membrane, or short-range transport along filamentous actin (F-actin) filaments 
randomly oriented in the cytoplasm. Examples of motors that mediate traffic on 
microtubules are for example dynein, a minus-end oriented protein that mediates 
vesicle transport to the cell center (62), or kinesins, plus-end directed motor 
proteins that mediate outward transport (63). The only microtubule-independent 
protein that is suitable for long-range transport on actin-filaments is myosin, 
which however, has only very short tracks at its disposal. This classical textbook 
knowledge has recently been extended based on the finding that there was also 
long-range vesicle transport on actin tracks detectable that, furthermore was 
formin-dependent (64), indicating a possible role of Cdc42 in this mechanism. In 
brief, vesicles themselves recruit actin-nucleating factors Spire-1, Spire-2 and 
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Formin-2 that build up short actin filaments surrounding the vesicle surface. These 
short filaments connect the vesicle to the pre-existing actin network and initiate 
vesicle movement toward the cell surface in a Myosin-Vb-dependent manner (64). 
 
Besides these intracellular movements, vesicle formation is also important at the 
cell surface of APCs, such as DCs. It serves in acquisition of extracellular contents 
such as nutrients and involves membrane deformation, vesicle formation and 
scission followed by transport along the endocytic route. Depending on the mode 
of “sampling” different types of signaling cascades induce the recruitment of Rho 
GTPases (51). 
3.2.4 Rho GTPases are targets of bacterial toxins 
Due to their potential in reorganizing the actin cytoskeleton, it is not surprising 
that Rho family members have become targets of numerous bacterial toxins 
(reviewed in (65, 66)). The coherent mechanism of these toxins relies in the 
activation or deactivation of Rho GTPases, inducing local actin polymerization 
events (e.g. at the plasma membrane) facilitating bacterial entry into non-
phagocytic cells, or disrupting cytoskeleton dynamics required for APC motility, 
thereby promoting local bacterial cell invasivity. Many mechanisms involve the 
Rho GTPases Rac1, Cdc42 and RhoA with downstream signaling on the actin 
cytoskeleton and a variety of virulence factors have been identified that 
differentially regulate their activities (reviewed in (65) and (67)). Therefore, the 
mechanisms of action of Rac1, Cdc42 and RhoA remain important to fully 
understand their functions in DC biology upon encounter of pathogens. 
3.2.5 Functions of Cdc42 in DCs 
Until now, Cdc42 function has mostly been studied in non-hematopoietic cell lines 
using either mutant proteins or bacterial toxins. A global Cdc42 knockout is 
embryonic lethal (54). Therefore, Cdc42 function in DCs could only be studied 
in vitro by modulating Cdc42 activity in bone-marrow derived DCs (BMDCs). The 
following section briefly summarizes previous findings of how Cdc42 regulates 
cell shape, antigen acquisition and presentation. 
 
Filopodia and podosome formation 
The best-studied function of Cdc42 involves its regulation of the actin 
cytoskeleton, which is summarized in chapter 3.2.3. Actin dynamics are important 
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for general DC morphology and APC function. More specifically, dendrite 
morphology plays a role in the periphery for acquisition of antigens and DC 
migration, and in lymph nodes to maximize contact with T cells. Interestingly, a 
role of Cdc42 could be identified in the dendrite morphology of peripheral blood 
mononuclear cell (PBMC)-derived DCs and their adhesion capacity to fibronectin-
coated surfaces using mutant proteins (68). Whereas DCs deficient for Cdc42 
activity showed strong retraction of dendrites, acceleration of Cdc42 activity 
caused strong DC spreading due to actin polymerization at active sites. The loss of 
Cdc42 function lead to a disruption of F-actin structures and diffuse intracellular 
localization of broke filaments. Another study in mature human Langerhans cell 
(LC)-type DCs showed that depletion of functional Cdc42 resulted in a loss of both 
filopodia and lamellipodia (69). This study also indicated a role of active Cdc42 
during both DC activation and MHC I surface expression. A developmental 
regulation of Cdc42 in DCs has been proposed in several publications (discussed 
in chapter 6.1.).  
 
A study using human PBMC-derived DCs established a role of Cdc42 in 
podosome formation, and the formation of important adhesion structures at the 
leading edge of migrating cells. DCs transfected with a dn-Cdc42 mutant showed 
an increase in cell polarity accompanied with a loss of filopodia in migrating cells 
(70). This study also showed that overexpression of Cdc42 in mature DCs lead to 
an extension of filopodia formation, which was, furthermore, WASP and Arp2/3-
dependent.  
 
Endocytosis and antigen presentation 
Besides the formation of large protrusive structures, Cdc42 also mediates small 
changes in membrane dynamics with an impact on antigen acquisition and 
presentation. Shurin and colleagues confirmed a function for Cdc42 in adhesion, 
endocytosis and antigen presentation using BMDCs (71). The authors extensively 
characterized these cells transfected with a dn-Cdc42 mutant, showing that DCs in 
the absence of functional Cdc42 protein showed reduced adhesion on polylysine 
slides, no role for motility using a transwell system and a reduced capacity to take 
up dextran and present an OVA-derived peptide to CD4+ T cells. In human LC-
derived DCs the loss of Cdc42 function was associated with an impaired capacity 
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to stimulate CD8+ T cells (69), probably due to low MHC I expression and 
costimulation of transduced mature DCs. 
DC endocytosis was already earlier shown to be dependent on Cdc42 function 
using immature BMDCs: Garrett and colleagues (72) identified a role of Cdc42 in 
macropinocytosis, receptor-mediated endocytosis and pinocytosis. Furthermore, 
they found that DC activation was accompanied with a shutdown of endocytosis, 
caused by a downregulation of Cdc42 activity. 
 
Altogether these studies point towards a contribution of Cdc42 in DCs in 
regulating processes required for basic APC functions like antigen acquisition, 
migration and antigen presentation. However, due to their usage of dn- or ca-
mutants of Cdc42, several of these studies lack specificity and mechanistic details 
required to understand how Cdc42 specifically contributes to DC-mediated 
immunity. 
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3.3 Aims of the study 
3.3.1 Characterization of a DC-specific knockout for Cdc42 
In order to avoid caveats due to an unspecific targeting of mutant proteins or 
toxins (see 3.2.2) we used a novel knockout mouse that conditionally lacks Cdc42 
expression only in CD11c+ cells, thereby leaving other Rho GTPases in DCs, and 
other cell types in the mouse unaffected.  
We first aimed to characterize DCs derived from these mice (termed Cdc42-ko) 
with respect to cell surface expression of immune molecules required for APC 
function. Furthermore, we wanted to study the functional consequences of Cdc42 
removal on important APC functions such as endocytosis, antigen acquisition and 
T cell stimulation in Cdc42-ko DCs, in order to investigate the role of specifically 
Cdc42 for these processes. 
3.3.2 Elucidation of the mechanism by which Cdc42 controls 
MHC II antigen presentation in DCs 
Based on the finding that Cdc42-ko BMDCs failed to induce CD4+ T cell responses, 
we aimed to elucidate the specific contribution of Cdc42 to MHC II antigen 
presentation. In order to get an unbiased overview of pathways affected upon 
Cdc42 removal, we wanted to investigate the proteome composition of Cdc42-ko 
BMDCs using proteomics. More specifically, we aimed to identify factors 
responsible for MHC II antigen presentation that might be affected upon Cdc42 
knockout. Given the role of Cdc42 in regulating actin dynamics, we aimed to 
study the contribution of the actin cytoskeleton to MHC II loading by chemically 
disrupting actin filaments. Furthermore, we wanted to identify a Cdc42-
dependent mechanism that regulates actin dynamics involved in MHC II loading, 
in order to define the specific contribution of Cdc42 for this process.  
3.3.3 Examination of MHC II loading in DC subsets 
Additionally, we aimed to study selected in vivo DC subsets of wild type (wt) and 
Cdc42-ko mice with respect to MHC II loading and investigate their potential to 
fully activate CD4+ T cells when pulsed with pre-processed OVA peptide.  
With this study we want to further expand the knowledge about the regulation of 
MHC II antigen presentation of exogenously derived antigens and describe the 
role of Cdc42 in adaptive immunity in vivo. 
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4 MATERIALS AND METHODS 
Materials are listed in alphabetical order. Methods are subdivided into 
cellular/immunological methods, biochemical methods and proteomics and 
within these subdivisions listed as they appear in the results section. Company 
headquarters are listed at first mention only. 
4.1 Materials 
4.1.1 Antibodies 
Table 1: Antibodies used for flow cytometry. 
Specificity (anti-mouse) Conjugate Clone Supplier 
CD3e PerCP 145-2C11 Becton, Dickinson & Co. 
(BD), Franklin Lakes, NJ, 
USA 
CD4 PE, PerCP CK1.5, RM4-5 BD 
CD8a APC-Cy7, PE, PerCP 53-6.7 BD 
CD11b PE M1/70 BD 
CD11c APC, Biotin, Pe-
Cy5.5, Pe-Cy7 
N418, HL3 eBioscience, San Diego, CA, 
USA, BD 
CD16/CD32 Purified  BD 
CD19 PerCP-Cy5.5 1D3 BD  
CD40 APC 1C10 eBioscience 
CD44 FITC IM7 BD 
CD62L APC MEL-14 BD 
CD74 FITC ln-1 BD 
CD86 PE GL1 BD 
CD90.1 APC, PerCP HIS51, OX-7 eBioscience, BD 
CD103 PE M290 BD 
CD107a  
(LAMP-1) 
FITC, PE eBio1D4B eBioscience 
F4/80 Biotin, PE BM8 eBioscience 
H2-Kb (MHC I) FITC, PE AF6-88.5 BD  
The table continues on the next page.  
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Streptavidin conjugates were purchased from BD (SA-PerCP) and eBiosciences 
(SA-Pe-Cy7). Dead cell exclusion DAPI and LIVE/DEAD® Violet Dead Cell Stain 
were purchased from Invitrogen (Life Technologies, Pailsey, UK). 
 
Table 2: Unconjugated Antibodies used for Western blot. 
Specificity (anti-mouse) Conjugate Clone Supplier 
I-Ab (MHC II) Alexa Fluor®647, 
Biotin, FITC 
AF6-120.1, 25-9-17 BD, BioLegend 
MHC class II FITC 15G4 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Vα2 TCR FITC B20.1 BD 
Vβ5.1/5.2 TCR PE MR9-4 BD 
anti-mouse IgG1 APC X56 BD 
anti-mouse IgG2a Alexa Fluor®647 MOPC-173 BioLegend 
anti-mouse IgG1 FITC - Santa Cruz  
Specificity  Clone Isotype Supplier 
β-Actin Polyclonal Rabbit IgG Cell Signaling Technology, Danvers, 
MA, USA 
Cathepsin D Polyclonal Goat IgG R&D Systems, Minneapolis, MN, 
USA 
Cathepsin L Polyclonal Goat IgG R&D  
Cathepsin S Polyclonal Goat IgG Acris Antibodies GmbH, Herford, 
Germany 
CD107a (LAMP-1) 1D4B Rat IgG BioLegend 
CD74 (Ii) ln-1 Rat IgG BD 
Cdc42 11A11 Rabbit IgG Cell Signaling 
Gapdh 14C10 Rabbit IgG Cell Signaling 
Hip1R 44/Hip1R Mouse IgG BD 
Rac1 ARC03 Mouse IgG Cytoskeleton, Inc., Denver, CO, USA 
RhoA 67B9 Rabbit IgG Cell Signaling 
β-Tubulin 9F3 Rabbit IgG Cell Signaling 
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Anti-rat horseradish peroxidase (HRP) was purchased from Cell Signaling. Anti-
rabbit, anti-goat and anti-mouse HRP were purchased from Jackson 
ImmunoResearch Laboratories (West Grove, PA, USA).  
4.1.2 Chemicals 
Unless stated otherwise, chemicals were purchased from Merck (Darmstadt, 
Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA).  
4.1.3 Consumables 
Cell strainer (100 µM, BD), disposable syringe 1 and 5 ml (Braun, Melsungen, 
Germany), disposable syringe filter 0.2+0.45 µm (Nalgene Nunc Int., Rochester, 
NJ, USA), disposable injection needle 26 Gx1/2“ (Terumo Medical Corporation, 
Tokyo, Japan), reaction container 1.5 ml und 2 ml (Eppendorf, Hamburg, 
Germany), reaction tube 5 ml (BD), reaction tube 15 ml und 50 ml (Greiner, 
Frickenhausen, Germany).  
 
Other materials and plastic wares were purchased from BD, Nunc (Wiesbaden, 
Germany) and Greiner. 
4.1.4 Devices 
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), automatic 
pipettors (Integra Biosciences, Baar, Switzerland), bench centrifuge (Centrifuge 
5415 D, Eppendorf, Hamburg, Germany), cell counter (Coulter Counter Z2, 
Beckman Coulter, Krefeld, Germany), centrifuge (Rotixa RP, Hettich, Tuttlingen, 
Germany), chemical scale (Kern, Albstadt, Germany), Coulter counter Z2 
instrument (Beckman Coulter), flow cytometer (FACSCantoII and FACSAria, BD), 
incubator (Hera cell, Heraeus Kendro Laboratory Products, Hanau, Germany), 
laminar airflow cabinet (Heraeus), magnetic stirrer (Ika Labortechnik, Staufen, 
Germany), Optimax® developing machine (Protec Medical Systems), pH-meter 
(Inolab, Weilheim, Germany), pipettes (Gilson, Middleton, WI, USA), Polymax 
1040 platform shaker (Heidolph, Schwabach, Germany), power supply 
(Amersham Pharmacia, Piscataway, NJ, USA), radiographic cassette 18x14 cm 
(Siemens), real-time PCR machine (CFX96 Real Time System, BIO-RAD), tank 
transfer system (BIO-RAD), Thermocycler PCR-machine (Biometra, Goettingen, 
Germany), vacuum pump (KNF Neuberger, Munzingen, Germany), vortex-
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Genie2 (Scientific Industries, Bohemia, NY, USA), water bath (Grant Instruments 
Ltd., Barrington Cambridge, UK). 
4.1.5 Inhibitors 
Cytochalasin D and Nocodazole were purchased from Sigma-Aldrich; Gö 6983, 
Latrunculin B and SMIFH2 were purchased from Calbiochem EMD Millipore 
(Billerica, MA, USA) and Concanamycin B and CK-548 delivered from Enzo 
(Lörrach, Germany). Pitstop 2 was purchased from Abcam (Cambridge, UK). 
4.1.6 Media and solutions 
Table 3: Cell culture media used in this study.  
All media supplementing solutions were purchased from Gibco (Invitrogen, Carlsbad, CA, USA) 
or PAN-Biotech (Aidenbach, Germany). 
 
 
 
 
 
 
 
Medium Supplementing solutions 
  
BMDC medium  
 
Iscove's Modified Dulbecco's Medium (IMDM, 
Sigma-Aldrich) 
500 mM β-mercaptoethanol 
2 mM glutamine 
100 U/ml penicillin 
100 µg/ml streptomycin 
10 % FCS (heat inactivated) 
20 ng/ml GM-CSF 
DC medium RPMI 1640 + glutamine  
(PAA, Pasching, Austria) 
500 mM β-mercaptoethanol 
100 U/ml penicillin 
100 µg/ml streptomycin 
10 % FCS (heat inactivated) 
20 ng/ml GM-CSF 
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Table 4: Buffers and solutions. 
All buffers and solutions were prepared using double distilled water. 
Buffers and Solutions Composition 
  
ACK 8.29 g NH4Cl 
1 g KHCO3 
37.2 mg Na2EDTA 
H2O ad 1 l 
pH 7.2-7.4 adjusted with HCl 
sterilized by 0.2 µm filtration 
  
PBS 150 mM NaCl 
10 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4 adjusted with 5 N NaOH 
  
PBS (cell culture) Dulbecco’s PBS without Ca2+/Mg2+ (PAA) 
  
FACS buffer PBS 
2 % FCS 
0.01 % NaN3  
  
MACS buffer PBS 
0.5 % FCS  
  
10x Gitocher buffer 670 mM Tris, pH 8.8 
166 mM ammonium sulfate 
65 mM MgCL2 
0.1 % Gelatin 
  
5x Cresol red buffer 250 mM KCL 
50 mM Tris/HCL pH 8.3 
43 % glycerol 
2 mM Cresol-red 
7.5 mM MgCl2 
  
50x TAE buffer 242 g Tris 
57.1 ml 100 % acetic acid 
100 ml 0,5 M EDTA (pH 8.0), H2O ad 1 l 
  
SDS running buffer 192 mM Glycin 
25 mM Tris 
0.1 % SDS 
 
The table continues on the next page.  
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Buffers and Solutions Composition 
  
Transfer buffer 192 mM Glycin 
25 mM Tris 
20 % Methanol 
0.002 % SDS  
  
“Stripping” buffer 62.5 mM Tris  
pH 6.7 adjusted with HCL 
100 mM β-mercaptoethanol 
2 % SDS 
  
PBST PBS 
0.05 % Tween-20 
  
5x SDS sample buffer 50 % Glycerin  
250 mM Tris  
pH 6.8 adjusted with HCL 
500 mM DTT 
10 % SDS 
0.5 % bromphenol blue 
  
NP-40 cell lysis buffer 50 mM Tris 
pH 8.0 adjusted with HCL 
150 mM NaCl2 
1 % NP-40 
Protease inhibitor cocktail 1x 
add 1 mM PMSF before use 
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Table 5: Preparation of gels for SDS Page. 
Volumes in brackets apply to the amount required for 2 gels. 
4.1.7 Mouse strains 
Cdc42flx-Cre mice (termed Cdc42-ko) were generated by breeding CD11c-Cre+ 
mice (73), kindly provided by Boris Reizis (Columbia University, New York, NY), 
with Cdc42fl/fl mice (74), kindly provided by Cord Brakebusch (University of 
Copenhagen, Copenhagen, Denmark). OT-I and OT-II mice (expressing a 
transgenic TCR specific for OVA257–264 or OVA323–339, respectively) and C57BL/6 
CD45.1+ mice were originally obtained from The Jackson Laboratory (Bar Harbor, 
ME, USA). Mice were bred and maintained in a conventional facility at the 
Institute for Immunology (Munich, Germany) and used according to protocols 
approved by the local animal ethics committee. 
4.1.8 Fluorescent probes, proteins, peptides and primers 
(I) Fluorescent probes: Alexa Fluor®647-conjugated OVA (Alexa-OVA), FITC-
dextran and Lucifer yellow CH lithium salt were all purchased from Molecular 
Probes (Invitrogen). 
(II) Proteins and Peptides: OVA grade VII (peptide-free) was purchased from 
Sigma-Aldrich; the peptides SIINFEKL (OVA257-264) and P323-339 (OVA323-339) were 
obtained from NeoMPS (Strasbourg, France). 
Gel Composition 
  
Resolving gel (12 %) H2O (6.6 ml) 
30 % acrylamide mix (8 ml) 
1.5 M Tris/HCL, pH 8.8 (5 ml) 
10 % SDS (200 µl) 
10 % ammonia persulphate (200 µl) 
TEMED (20 µl) 
  
Stacking gel H2O (2.1 ml) 
30 % acrylamide mix (500 µl)) 
1 M Tris/HCL, pH 6.8 (380 µl) 
10 % SDS (30 µl) 
10 % ammonia persulphate (30 µl) 
TEMED (3 µl) 
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(III) Primers: All oligonucleotides were purchased from MWG-Biotech AG 
(Ebersberg, Germany). Primer sequences are listed in the respective methods 
sections. 
4.2 Methods 
4.2.1 Cellular and immunological methods 
4.2.1.1 Generation of bone marrow-derived dendritic cells (BMDCs) 
Primary cultures of immature DCs were generated by culturing bone marrow 
cells, isolated from femurs and tibiae of mice (see 4.2.1.9 and 4.2.1.10), for 10-14 
days in BMDC medium (Table 3) containing 20 ng/ml GM-CSF. Cells were passed 
at days 3 and 7 and plated at a concentration of 1.5x106 cells/ml. BMDCs were 
analyzed by flow cytometry based on the expression of CD11c, MHC II and CD86. 
Mature BMDCs were obtained by overnight stimulation with 1 µg/ml 
lipopolysaccharide (LPS, Sigma-Aldrich). 
4.2.1.2 Flow cytometry – Fluorescence activated cell sorting (FACS) 
Flow cytometry is a method used for the evaluation of various characteristics of 
cells such as cell size (forward scatter, FSC), granularity (side scatter, SSC) and 
fluorescence intensity. In brief, single cell suspensions are labeled with fluorescent 
antibodies specific for cell type specific molecular markers and pass by a focused 
laser beam, which stimulates the fluorophores. The emitted light from the 
fluorophores can then be detected concomitantly with the scattered light 
generated by these cells. Thus, this technique can be used to identify distinct cell 
populations within a heterogeneous mixture of cells. The flow cytometer used in 
this study was the FACSCanto II (BD) equipped with three lasers (488, 633 and 
405 nm). A FACSAria instrument (BD) was used to sort DCs from splenic single 
cell suspensions based on electrostatic droplet deflection. Data from flow 
cytometry were analyzed with the FlowJo software (TreeStar, Ashland, OR, USA). 
 
Staining of cells with fluorescent antibodies:  
Equal numbers of cells were mixed with 100 µl of FACS buffer containing specific 
antibodies of interest and incubated at 4 °C in the dark. After 20 min, cells were 
washed with 2 ml FACS buffer to remove unbound antibodies (180xg, 4 °C). 
Biotinylated antibodies were detected in a second step using fluorescent 
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streptavidin-conjugates. Stained cells were passed over a filter (41 µm mesh, 
Reichelt Chemietechnik, Heidelberg, Germany) to obtain single cell suspensions. 
4.2.1.3 Antigen uptake & presentation 
For antigen uptake, immature BMDCs were harvested, resuspended at a 
concentration of 1x106 cells/ml in serum-free IMDM containing 5 µg/ml Alexa-
OVA, 1 mg/ml FITC-dextran and 0.5 mg/ml Lucifer yellow and were then 
incubated at 4 °C or 37 °C for 20 min. Uptake was stopped with 4 washes in ice-
cold FACS-buffer. Cells were then stained with fluorescent antibodies and 
analyzed by flow cytometry. In a second experiment, Alexa-OVA was titrated to 
visualize how much OVA was taken up by cells that were used for a T cell 
proliferation assay (Figure 6B). BMDCs at day 13 of culture were incubated with 5, 
25 ot 125 µg/ml Alexa-OVA for 3 h and then stimulated with 1 µg/ml LPS 
overnight. Cells were then stained with fluorescent antibodies and analyzed by 
flow cytometry. 
 
Antigen presentation was examined by co-culturing antigen-loaded BMDCs with 
CFSE-labeled OVA-specific T cells (see 4.2.1.11). For the presentation of whole 
protein antigen immature BMDCs were pulsed with 5, 25 or 125 µg peptide-free 
OVA for 3 h, stimulated overnight with 1 µg/ml LPS. BMDCs were next co-
cultured together with T cells in BMDC medium at a DC:T cell ratio of 1:20 in 96-
well round-bottom plates for 3 d. For the presentation of pre-processed OVA 
peptides, BMDCs were first matured overnight in the presence of LPS and 
incubated with 0.1, 1, 10 and 100 pg/ml SIINFEKL peptide or 0.01, 0.1, 1 and 
10 µg/ml P323-339 peptide for 3 h. Peptide-loaded BMDCs were washed 3x and 
subsequently co-cultured with T cells at a DC:T cell ratio of 1:40 with OT-I or OT-II 
cells for 3 and 4 days, respectively. T cells were stained with fluorescent antibodies 
and T cell proliferation was examined from CFSE dilution. 
4.2.1.4 Antigen processing  
BMDCs were incubated with 50 µg/ml of a non-fluorescent self-quenched 
conjugate of ovalbumin (DQ-OVA, Molecular Probes) that exhibits fluorescence 
upon proteolytic degradation. 5 µg/ml non-degradable Alexa-OVA (see 4.1.8) in 
the same mix served as positive control for protein uptake. After 15 min uptake, 
cells were washed with FACS buffer to remove excess antigen and re-incubated at 
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37 °C for additional 15 min in BMDC medium to allow DQ-OVA processing. Cells 
were then stained for flow cytometry and analysis was performed gating on 
CD11c+Alexa-OVA+ cells. 
4.2.1.5 Inhibitor treatment of cultured cells 
BMDCs were treated with small molecules that specifically inhibit processes 
required for basic cell functions. These freely membrane permeable molecules 
were applied to Wt BMDC cultures for 16 h (overnight).  
Table 6 lists the inhibitors, their specificities and the final concentrations they were 
used at. 
Table 6: Inhibitors used in this study.  
Suppliers are listed in chapter 4.1.5. 
4.2.1.6 Internalization of invariant chain from the cell surface of DCs 
BMDCs were labeled for surface invariant chain bound to I-Ab at 4 °C using a 
purified anti-mouse 15G4 mAb (Santa Cruz). Unbound antibody was removed 
and cells were allowed to internalize surface proteins in the presence of complete 
medium at 37 °C, 5 % CO2. At the indicated times, cells were transferred to 4 °C 
and remaining antibodies at the cell surface were detected using a secondary APC 
rat anti-mouse IgG1 antibody (BD Pharmingen). Cells were analyzed by flow 
cytometry and relative fluorescence intensity (rFI) values of CD11c+ cells were 
calculated as described elsewhere (84) using the following equation:  
rFI = [MFI(specific antibody) – MFI(isotype control) ] / MFI(isotype control). 
Inhibitor Specificity Final concentration(s) References 
CK-548 Arp3  100, 50, 25, 12.5, 6.25 µM (75) 
Concanamycin B V-ATPase 2 nM (76, 77) 
Cytochalasin D Actin cytoskeleton 10 µg/ml (78) 
Gö 6983 Protein kinase C (PKC) 1 µM (59, 74) 
Latrunculin B Actin cytoskeleton 1 µg/ml (79, 80) 
Nocodazole Tubulin 30 µM (81) 
Pitstop 2 Clathrin heavy chain 30, 10, 5 µM (82) 
SMIFH2 Formin FH2 domain 10 µM (83) 
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4.2.1.7 Cytometric Bead Array (CBA) 
The Mouse Inflammation Kit (BD) was used to quantitatively detect inflammatory 
cytokines in BMDC culture supernatants. The kit follows the CBA principle, which 
is analogous to conventional ELISAs, but allows detection of several different 
proteins in one multiplexed assay. In brief, a mixture of beads coated with capture 
antibodies specific for IL-6, IL-10, monocytic chemotactic protein 1 (MCP-1), 
interferon gamma (IFN-γ), TNF and IL-12p70 proteins was applied to culture 
supernatants and detected with a secondary, PE-conjugated antibody. Samples 
including a standard curve were acquired by flow cytometry on a FACSCanto II 
(BD) instrument and analyzed using the FCAP Array Software v1.0.2 (Soft Flow, 
BD). Supernatants were used undiluted; LPS-treated BMDC culture supernatants 
were used as positive control and diluted 1:4. The assay was performed according 
to the manufacturer’s instructions. 
4.2.1.8 Magnetic cell sorting (MACS) 
MACS is a technique used to enrich cell populations according to their expression 
of cell type specific surface markers. Two different methods are available: positive 
and negative selection. For positive selection, magnetic beads are conjugated to 
monoclonal antibodies (here: anti-mouse CD11c mAb, clone N418) that label cells 
expressing this specific cell surface marker. After labeling, cells are loaded onto a 
magnetic column placed in a magnetic field that retains the magnetically labeled 
cells (here: CD11c+ cells) on the column. For negative selection, a cocktail of biotin- 
conjugated monoclonal antibodies that do not bind the cell population of interest 
itself is applied to the cell suspension.  In a second step, labeled cells bind to 
magnetic beads and are retained in the column and depleted from the cell 
suspension. Negative selection was applied for CD4+ or CD8+ T cell enrichment 
from splenic cell suspensions. Both the CD11c Microbeads and the CD4+ T cell 
isolation kit were purchased from Miltenyi Biotech (Bergisch Gladbach, Germany) 
and used according to the manufacturer’s instructions. 
4.2.1.9 Harvesting organs from mice 
Mice were sacrificed in a CO2 gas chamber, fixed with needles on a polystyrene 
pad, disinfected with 70 % ethanol and cut open. Lymph nodes and spleens were 
harvested with fine tweezers and kept on ice in PBS. For bone-marrow cultures, 
hind legs were cut, cleaned of muscle, separated into femurs and tibiae and kept 
on ice in PBS until use.  
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4.2.1.10 Isolation of cells from organs 
Bone marrow: The terminal parts of femurs and tibiae were cut open and the bone 
marrow was flushed out with needle and syringe using medium containing 10 % 
FCS. Red blood cells were lysed for 2 min in ACK buffer and the cell suspension 
was passed over a cell strainer to remove debris. Cells were subsequently 
subjected to cell culture, or frozen for future use in BMDC medium supplemented 
with 10 % extra FCS and 10 % dimethyl sulfoxide (DMSO) at -80 °C. 
 
Spleen and lymph nodes: For isolation of DCs from mouse spleens and lymph 
nodes, organs were enzymatically digested using a solution containing Liberase CI 
(0.42 mg/ml) and DNase I (0.2 mg/ml, both Roche, Basel, Switzerland). After a 
20 min incubation at 37 °C organs were mechanically disrupted using a pestle 
(Gerresheimer, Querétaro, México) and passed over a cell strainer to obtain a 
single cell suspension. Erythrocytes in splenic cell suspensions were lysed for 
5 min using ACK and the suspension was again passed over a cell strainer. The 
single cell suspension was used for flow cytometry, or enriched by MACS (see 
4.2.1.8) prior to use. 
4.2.1.11 CFSE labeling of T cells 
CFSE staining (Carboxyfluorescein diacetate succinimidyl ester, Life 
Technologies™) is a standard method used for the fluorescent labeling of cells. 
CFSE is a cell-permeable molecule that diffuses passively into cells and reacts with 
intracellular amines. It is colorless, but exhibits its fluorescence upon cleavage by 
intracellular esterases. In this study, CFSE staining was used to determine T cell 
proliferation. As T cells divide, CFSE fluorescence gets diluted, as the dye is 
equally distributed between the two daughter cells.  This effect results in the 
typical diagram that is characterized by a peak of non-dividing T cells showing 
undiluted CFSE fluorescence of high intensity, accompanied by a couple of peaks 
that are lower for CFSE and represent cell divisions.  
For CFSE labeling, purified CD4+ or CD8+ T cells (see 4.2.1.6) were resuspended at 
10x106 cells/ml in pre-warmed PBS containing 0.03 % FCS, and 5 µM CFSE was 
added while vortexing to ensure a homogenous labeling. Cells were incubated for 
10 min at 37 °C and vortexed every 2-3 min to ensure homogeneity of 
fluorescence. The reaction was stopped by adding an equal volume of pure FCS 
and cells were washed 3 times to remove unbound CFSE. After the staining 
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procedure, T cells were counted and co-cultured together with BMDCs (see 
4.2.1.3). 
4.2.1.12 Immunization and adoptive cell transfer 
To investigate the presentation of OVA323-339 peptide (P323-339) in vivo, 2x106 
transgenic CD4+CD90.1+ OT-II cells, isolated from lymph nodes of OT-II mice and 
enriched by negative selection (MACS), were adoptively transferred intravenously 
into wt and Cdc42-ko recipients. The next day, mice were challenged with a single 
dose of 20 µg LPS and 100 µg P323-339 peptide in PBS. After five days, mice were 
sacrificed and spleens were analyzed for the presence of CD4+CD90.1+ T cells. A 
no-peptide control was used to exclude any unspecific proliferation of transgenic 
T cells. 
4.2.2 Molecular biology and biochemical methods 
4.2.2.1 Mouse genotyping 
Table 7: Isolation of genomic DNA and mouse genotyping. 
The genotype of Cdc42-ko mice was determined by PCR on genomic DNA isolated from mouse 
tails. PCR products were analyzed by conventional agarose gel electrophoresis in comparison to a 
1 kb ladder (New England Biolabs, Ipswich, MA, USA). 
Isolation of genomic DNA from mouse tails 
 
Isolation of genomic DNA: 1x Gitocher buffer (see Table 4) 
0.5 % Triton-X 
1 % ß-mercaptoethanol 
0.4 mg/ml proteinase k 
H2O ad 50 µl 
 6 h at 55 °C and 95 min at 95 °C 
  
Composition of PCR reaction: 1 µl DNA 
6 µl Cresol red buffer with MgCl2 
100 pM primer for  
100 pM primer rev 
2.5 mM dNTP mix  
5 U/ml PANScript DNA polymerase  
H2O ad 29 µl 
Primer sequences and genotyping 
Cdc42 fl/fl PCR:  
Cdc42-for 5’-TCTGCCATCTACACATACAC-3’ 
Cdc42-rev 5’-ATGTAGTGTCTGTCCATTGG-3’ 
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4.2.2.2 RNA isolation and complementary DNA (cDNA) synthesis 
RNA was isolated from total cells using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. To remove any 
contaminating DNA, the optional on-column DNase digestion step with RNAse-
free DNAse was included. The concentration of RNA was determined with a 
NanoDrop instrument (Thermo Fisher Scientific, Waltham, MA, USA). Equal 
amounts of RNA were then used for cDNA synthesis with the SuperScript® 
VILO™ cDNA Synthesis Kit (Invitrogen) according to the manufacturer’s 
instructions. 
4.2.2.3 Quantitative PCR (qPCR) 
qPCR allows simultaneous amplification of cDNA templates and is used to 
determine the exact quantity of a particulate cDNA and thereby, RNA sequence. 
qPCR was performed using two different methods, SYBR Green and TaqMan, 
both based on the detection of a fluorescent reporter molecule that accumulates 
with each cycle of amplification. In brief, SYBR is a fluorescent dye that 
Products: 300 bp (flx); 160 bp (wt) 
  
PCR program:  
Step 1: 95 °C 2 min 
Step 2: 65 °C 30 s -Δ-1 cycle 
Step 3: 75 °C 45 s - back to step 1 (10x) 
Step 4: 95 °C 30 s 
Table 7 continued:  
Step 5: 55 °C 30 s 
Step 6: 72 °C 45 s - back to step 4 (35x) 
Cre PCR:  
Cre-for  5’-GGACATGTTCAGGGATCGCCAGGCG-3’ 
Cre-rev 5’-GCATAACCAGTGAAACAGCATTGCTG-3’ 
Products: 270 bp (Cre); none (wt) 
  
PCR program:  
Step 1: 95 °C 5 min 
Step 2: 95 °C 30 s -Δ-1 cycle 
Step 3: 55 °C 30 s  
Step 4: 72 °C 45 s - back to step 2 (35x) 
Step 5: 72 °C 5 min 
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intercalates into any double stranded DNA. TaqMan, on the other hand, makes 
use of specific fluorescent probes that hybridize with the respective amplification 
products. The cycle number (crossing point, CP), at which the fluorescence 
exceeds certain intensity, is then correlated with the initial amount of the relevant 
template cDNA, which can then be assigned to RNA levels.  
For both SYBR Green and TaqMan, 10 ng of cDNA was used per reaction and each 
sample was measured in technical duplicates on a CFX96 Real Time System (BIO-
RAD). 
 
The SYBR Green reaction was performed using the Lightcycler FastStart DNA 
MasterPLUS SYBR Green I Kit (Roche) according to the manufacturer’s 
instructions using the primers b2M-forward 5’-CAGAAAACCCCTCAAATTC 
AAGTAT-3’ and reverse 5’-AATTCAGTGTGAGCCAGGATATAGA-3’ (85). 
Expression levels were normalized to hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) (primer sequences see Table 8). 
 
The TaqMan assay was performed with the LightCycler TaqMan Master Kit 
(Roche) and the Universal ProbeLibrary Set mouse (Roche) according to the 
manufacturer’s instructions using the primers and probes listed in Table 8. 
Expression levels were normalized to ubiquitin C (UbiC), HPRT or 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). 
4.2.2.4 Preparation of lysates for Western blot 
Cells dedicated for Western blot were washed once with PBS to remove 
extracellular proteins, pelleted and resuspended at a concentration of 1x106 cells 
per 15 µL of Nonidet P-40 (NP-40) cell lysis buffer (see 4.1.5) in the presence of 
protease inhibitors (Protease Inhibitor Cocktail P8340 and phenylmethylsulfonyl 
fluoride (PMSF) (both Sigma-Aldrich). Cells were lysed for 15 min on ice, followed 
by 5 min centrifugation at 2500xg to remove intact nuclei and insoluble cellular 
debris. Both, total cell lysates and supernatants were quantified using the Quant-
iT™ Protein Assay Kit (Molecular Probes) to determine the exact protein 
concentration. Equal amounts of protein were then denatured using sodium 
dodecyl sulfate (SDS) sample buffer (see 4.1.5) at 96 °C for 7 min and further 
subjected to SDS Page and Western blot. 
 
MATERIALS AND METHODS 
 
 33 
Table 8: Primers and fluorescent probes used for TaqMan-based qPCR. 
4.2.2.5 SDS Page and Western blot 
Equal amounts of protein were loaded onto a 12 % SDS gel prepared as described 
in the Current Protocols in Immunology (Unit 8.9; see also Table 5) and separated 
by gel electrophoresis for 1.5 h at 80-100 V. PageRuler™ prestained protein ladder 
(Thermo Scientific, Rockford, IL USA) was loaded as a protein standard. Separated 
proteins were transferred onto a nitrocellulose membrane (Whatman) using a tank 
transfer system (BIO-RAD) as described in the Current Protocols in Immunology 
(Unit 8.10); transfer time was adjusted to 1.5 h at 80 V. Membranes were blocked 
overnight in PBS supplemented with 0.5 % Tween-20 and 5 % milk. 
 Gene Forward primer Reverse primer  Probe # 
 Cd40 
 
5’-GAGTCAGACTAATGTCAT 
CTGTGGTT-3’ 
5’-ACCCCGAAAATGGTGATG-3’  105 
 Cd74 5’-CACCGAGGCTCCACCTAA-3’ 5’-GCAGGGATGTGGCTGACT-3’  72 
 Cd86 5’-CCTCCAAACCTCTCAATTT 
CAC-3’ 
5’-GGAGGGCCACAGTAACTGAA-3’  12 
 Cdc42 5’-ACAACAAACAAATTCCCA 
TCG-3’ 
5’-TTGCCCTGCAGTATCAAAAA-3’  22 
 Ctsd 5’-CCCTCCATTCATTGCAAGA 
TAC-3’ 
5’-TGCTGGACTTGTCACTGTTGT-3’  3 
 Ctsl 5’-ACAGAAGACTGTATGGCAC 
GAA-3’ 
5’-GGATCATTCTCATGTTCTTCT 
CC-3’ 
 25 
 Ctss 5’-CATCTTTGGAGTGAGCACCA-3’ 5’-GCATCCAAAACAGCCATCTTA-3’  92 
 Gapdh 5’-GGGTTCCTATAAATACGGAC   
TGC-3’ 
5’-CCATTTTGTCTACGGGACGA-3’  52 
 H2-Ab1 5’-CACAGGAGTCAGAAAGGAC 
CTC-3’ 
5’-GTCAAAACACTCTGAGTCACT 
GC-3’ 
 
 25 
 Hprt1 5’-TCCTCCTCAGACCG CTTTT-3’ 5’-CCTGGTTCATCATCGCTAATC-3’  95 
 Lamp1 5’-CCTACGAGACTGCG AATGGT-3’ 5’-CCACAAGAACTGCCATTTTTC-3’  110 
 UbiC 5’-GACCAGCAGAGGCT GATCTT-3’ 5’-CCTCTGAGGCGAAGGACTAA-3’  11 
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4.2.2.6 Western blot quantification 
After incubation with specific primary and secondary antibodies (see 4.1.1, 
Table 2), membranes were developed using enhanced chemiluminescence (ECL) 
Western blotting substrate (PerkinElmer Inc., MA, USA) followed by exposure to 
Amersham Hyperfilm™ (GE Healthcare). Specific bands were quantified relative 
to actin, tubulin or Gapdh, as indicated in the figure legends, using the free online 
tool ImageJ (86) according to Luke Miller’s instructions 
(www.lukemiller.org/journal/2007/08/quantifying-Western-blots-without.html, 
Image J method version 2, as of December 2012). 
 
4.2.3 Quantitative proteomics and data analysis 
4.2.3.1 Quantitative proteomics 
Quantitative proteomics were performed for two biological replicates in 
collaboration with Stefan Lichtenthaler’s group at the German Center for 
Neurodegenerative Diseases (DZNE) Munich. Sample preparation for mass 
spectrometry was done as described (87). In brief, approximately 20x106 cells were 
lysed. Lysates were centrifuged at 10.000xg to remove insoluble cellular debris. 
Upon addition of five volumes of 8 M urea, one fifth of the cell lysate was 
subjected to filter-aided sample preparation (88) and fractionated into 5 fractions 
using StageTip-based SAX fractionation (87). Two technical replicates of each 
fraction were measured on a liquid chromatography-tandem mass spectrometry 
(LC-MSMS) set-up coupling a Proxeon Easy nLCII (Thermo Fisher Scientific) with 
in-house packed 15 cm columns (2.4 µm C18 beads) to an linear ion trap LTQ 
Velos Orbitrap mass spectrometer. A TOP14 method was used for data dependent 
peptide fragmentation. Data were analyzed by label-free quantification (see 
below). 
4.2.3.2 Label-free quantification 
Label-free quantification and analysis of the data was performed using the 
MaxQuant software suite (version 1.1.1.36) with the integrated Andromeda 
algorithm for protein identification searching a murine IPI database (version 3.78). 
Standard settings for the algorithm were used (89, 90). Quantification was 
performed on the basis of unique peptides: proteins detected with four unique 
peptides were considered “identified”. Differences in protein expression between 
wt and Cdc42-ko BMDCs were defined as fold-change values Cdc42-ko/wt. 
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4.2.3.3 Web-based evaluation of identified proteins 
The data set obtained from the proteomics approach was analyzed using the free 
online tools listed in Table 9. These tools are databases with different scopes, such 
as detailed information on single proteins (Uniprot), or lists of proteins that can be 
grouped under certain keywords (Gene Onthology). Their specifications are listed 
in the table. 
Table 9: Web pages used to analyze the proteomics data set. 
As of December 2012. 
Web page  Description 
www.uniprot.org Protein knowledge base 
www.string-db.org  Search tool for the retrieval of interacting genes 
and proteins 
www.genome.jp/kegg/pathway.html Collection of manually drawn pathway maps 
www.geneontology.org Collection of biological terms, for which 
proteins are grouped according to a biological 
process, cellular component or molecular 
function they are associated with 
 
4.2.4 Statistical analysis 
Significance was determined using the Student’s T test and defined as follows: 
*p<0.05, **p<0.01 and ***p<0.001. Bar graphs show average ± standard error of the 
mean (SEM) from single or combined experiments as indicated in the figure 
legends.
         CDC42 AND DC FUNCTION 
 
 36 
5 RESULTS 
5.1 Cdc42 maintains DC functions critical for the induction 
and control of immune responses 
5.1.1 A novel DC-specific knockout for Cdc42 
In order to study Cdc42 function in DCs we established a model system that did 
not require dnCdc42 constructs, thereby preventing unspecific effects caused by 
these mutants. Moreover, this novel knockout mouse lacks Cdc42 selectively in 
DCs, leaving other cell types Cdc42-sufficient. Thus, we were able to generate a 
DC-specific knockout with no constraints regarding the viability of mice, in 
contrast to a global Cdc42 knockout that was embryonic lethal (54). 
We generated Cdc42-ko mice by breeding Cdc42fl/fl mice (74) with CD11c-Cre 
mice (91) (Figure 3A). These mice express Cre recombinase (Cre) under the control 
of the CD11c promotor and therefore specifically in DCs. Once expressed, Cre 
binds to LoxP sites, which are integrated into exon 2 of the Cdc42 gene. Cre 
mediates recombination of LoxP sites, thereby excising a genomic region leading 
to the expression of non-functional Cdc42 mRNA (Cdc42 mutant). 
 We first tested the efficiency of the model system by analyzing in vitro generated 
BMDCs of control mice expressing Cre only (termed wt) and Cdc42-ko mice 
(termed Cdc42-ko) for residual Cdc42 protein and mRNA expression. BMDCs 
were generated by culturing bone marrow in the presence of GM-CSF, which is a 
 
Figure 3: Cre/LoxP approach to target Cdc42 selectively in DCs.  
(A) The CD11c-promotor driven expression of Cre recombinase (Cre) and the conditional Cdc42 
allele. CD11c-Cre recombinase is expressed specifically in DCs under the control of the CD11c 
promoter. Upon CD11c-Cre mediated recombination, the genomic region between the two LoxP 
sites is excised, inactivating the Cdc42 gene and resulting in non-functional Cdc42 mRNA (Cdc42 
mutant). Figure adapted from Benninger et al., 2007 (73) (B) Western blot analysis of bone marrow-
derived dendritic cells (BMDCs) revealed the absence of Cdc42 protein in Cdc42-ko cells. For 
qPCR, BMDCs were purified by CD11c-MACS prior to RNA isolation. Knockout-specific primers 
were used that detect only functional Cdc42 mRNA. Results are representative for three 
independent experiments with similar results.  
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growth factor required for DC differentiation. A long-term BMDC culture of 10-14 
days ensured that after shut down of functional Cdc42 mRNA production residual 
protein was degraded, generating a complete knockout for both Cdc42 protein 
and mRNA (Figure 3B). We also analyzed FACSAria sorted CD11c+MHC II+ 
spleen DCs out of Cdc42-ko mice for both Cdc42 protein and mRNA where we 
could detect low amounts of residual Cdc42 protein by Western blot (Paper I, 
Supplementary Figure S1D), but no functional Cdc42 mRNA in spleen DCs from 
Cdc42-ko mice (data not shown).  Notably, BMDCs (Figure 3B) as well as spleen 
DCs from Cdc42-ko mice (data not shown), albeit deficient for Cdc42, expressed 
comparable amounts of RhoA and Rac1, indicating that the expression of these 
two Rho GTPases was not affected upon Cdc42 knockout.    
 
5.1.2 Phenotype of Cdc42-ko BMDCs 
In order to study the function of Cdc42 in DCs, BMDCs were used as a model 
system. BMDCs, generated in the presence of GM-CSF, can be grown in large 
numbers and facilitate the analysis of DC-functions in vitro.  
Figure 4A shows representative FACS blots of unstimulated, steady-state wt and 
Cdc42-ko BMDC cultures (left panel). The purity of DCs (CD11c+) cells was 
typically around 95 % after 10-12 days of culture, the time point at which most of 
the experiments were performed. Unstimulated BMDCs were defined immature 
based on their low expression of MHC II and co-stimulatory molecules (e.g. 
CD86). Stimulated, mature DCs were obtained by culturing BMDCs in the 
presence of LPS overnight (right panel).  
DCs (CD11c+ cells) were further analyzed based on the expression of several 
surface markers important for DC function. Histograms show the expression 
levels of MHC I, MHC II, CD40, CD86, CD80, CD70, chemokine (C-C motif) 
receptor 7 (CCR7), CD45 and CD11c on wt vs. Cdc42-ko BMDCs (Figure 4B). Bar 
graphs show a quantification of selected surface markers based on mean 
fluorescence intensity values (MFI), on unstimulated vs. stimulated Cdc42-ko 
relative to wt cells (Figure 4C). 
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Figure 4: Phenotype of Cdc42-ko BMDCs. 
(A) Wt and Cdc42-ko BMDCs were analyzed for the expression of CD11c and MHC II. Numbers in 
FACS blots show DC frequencies for representative wt and Cdc42-ko cultures as frequencies of 
CD11c+ cells. Stimulated, mature BMDCs were obtained by overnight treatment with LPS. (B) 
Histograms show the expression of indicated surface markers on unstimulated and overnight with 
LPS stimulated CD11c+ BMDCs. (C) Mean fluorescense intensity values (MFI) for selected surface 
markers were determined gating on CD11c+ cells, as shown in B. Bar graphs and statistics show 
combined data of a minimum of 5 independent experiments with n≥2. 
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Unstimulated Cdc42-ko BMDCs showed surprisingly low amounts of both cell 
surface MHC I and MHC II, as compared to wt cells, but normal or higher 
expression of the co-stimulatory molecules CD40 and CD86 (Figure 4B and C). 
Interestingly, upon maturation with LPS Cdc42-ko BMDCs were able to 
upregulate MHC II and co-stimulatory molecules, thereby obtaining a mature 
phenotype. However, MHC I surface expression stayed low on these mature 
Cdc42-ko BMDCs, suggesting a function for Cdc42 in MHC I antigen presentation. 
Further markers evaluated in this manner were CD80 and CD70 (Figure 4B); two 
proteins that are upregulated at the cell surface upon maturation and play roles in 
T cell activation. Both were expressed at normal or higher amounts on Cdc42-ko 
BMDCs, similar to what was observed for the co-stimulatory molecules CD40 and 
CD86. CCR7, on the other hand, a chemokine receptor required for DC migration, 
was expressed at very low amounts on unstimulated Cdc42-ko BMDCs and was 
not properly upregulated in the absence of Cdc42. Similarly, two markers 
expressed by all DC subtypes, CD45 also known as leukocyte common antigen 
(LCA) and CD11c, were expressed at slightly reduced amounts on both 
unstimulated and stimulated Cdc42-ko DCs. Cell size of Cdc42-ko BMDCs, as 
determined from FSC-A acquisition, a parameter proportional to cell-surface area 
or size, was slightly reduced (Figure 4B). This phenotype was, however, 
statistically not significant.  
Immature DCs possess a large pool of intracellular MHC I and MHC II, which is 
redistributed to the cell surface upon maturation (Figure 4B). To investigate, 
whether the low expression of both MHC I and MHC II on immature Cdc42-ko 
DCs was due to decreased intracellular protein levels, we performed intracellular 
FACS analysis. Interestingly, Cdc42-ko DCs showed normal levels of intracellular 
MHC II, but a low expression of intracellular MHC I, which was, however, 
statistically not significant (Figure 5A). To evaluate, if this decrease in intracellular 
MHC I protein expression was due to lower MHC I transcription, we performed 
qPCR and found normal levels of β2M (soluble MHC I β-chain) message 
(Figure 5B) in unstimulated Cdc42-ko cells. H2-Ab1 (MHC II β-chain) mRNA was 
also expressed at normal amounts in these cells, which indicates that in the 
absence of Cdc42 both intracellular and surface levels of MHC molecules are most 
likely regulated post-transcriptionally, at the protein level. However, we did not 
assess the mRNA expression of the membrane-bound MHC I heavy chain (α-
chain) in this manner. 
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5.1.3 Cdc42 is required for uptake, but not processing of soluble 
antigen 
MHC molecules at the cell surface of DCs are loaded with antigens that are 
presented to antigen-specific T cells. Both MHC I antigen cross-presentation and 
MHC II antigen presentation require exogenously derived antigens that have to be 
actively taken up by the cell. Depending of the nature of antigen, DCs use 
different routes of uptake that can be addressed using proteins that target 
different mechanisms: OVA is taken up by both receptor mediated endocytosis 
and fluid-phase uptake (macropinocytosis), dextran specifically targets mannose-
receptor (MR) mediated endocytosis and Lucifer yellow lithium salt enters the cell 
via its constitutive fluid-phase uptake (pinocytosis).  
Thus, we targeted macropinocytosis, MR-mediated endocytosis and pinocytosis in 
wt vs. Cdc42-ko BMDCs using limiting amounts of the fluorescent proteins Alexa-
OVA, FITC-dextran and Lucifer yellow. Interestingly, similar frequencies of 
Cdc42-ko BMDCs were capable of Alexa-OVA uptake after 20 min of incubation 
with the antigen (Figure 6A, upper left panel). However, the amount of protein, as 
observed from MFI (Alexa-OVA) of CD11c+ cells, was severely reduced in the 
absence of Cdc42 (Figure 6A, upper right panel). Furthermore, we observed a 
reduced uptake capacity of Cdc42-ko BMDCs for both FITC-dextran and Lucifer 
yellow in both frequencies of antigen+ cells and MFI. These results are in 
agreement with previously published studies that used BMDCs depleted of 
functional Cdc42 with help of dominant negative mutants (72).  
 
 
Figure 5: Both MHC I and MHC II expression on Cdc42-ko BMDCs are regulated on protein 
level. 
(A) Intracellular FACS analysis of MHC I and MHC II was performed after fixation and 
permeabilization of wt and Cdc42-ko BMDCs. MFI were calculated gating on CD11c+ cells. (B) 
MHC I (β2M) and MHC II (H2-Ab1) mRNA were measured by qPCR from unstimulated BMDCs 
that were purified by CD11c positive selection (MACS) prior to RNA isolation. Data show a single 
experiment (n=2, β2M) and one representative experiment (n=2) out of three (H2-Ab1) normalized 
to HPRT or UbiC, respectively. 
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Next, we tested whether antigen uptake could be rescued in the absence of Cdc42 
by increasing antigen concentrations and/or time of antigen uptake. Therefore, wt 
and Cdc42-ko BMDCs were allowed to take up high amounts of Alexa-OVA for 
three hours followed by overnight incubation in the presence of LPS, and 
interestingly neither time, nor large amounts of antigen could increase the amount 
of Alexa-OVA taken up by Cdc42-ko cells (Figure 6B). After uptake, antigens 
require processing as a prerequisite for being loaded onto MHC molecules in 
specialized compartments. Therefore we investigated, whether antigen processing 
was Cdc42-dependent. We used a non-fluorescent self-quenched conjugate of 
ovalbumin (DQ-OVA) that exhibits fluorescence upon proteolytic degradation. 
The amount of processed DQ-OVA was calculated from MFI (DQ-OVA) gating on 
Alexa-OVA+ cells. Interestingly, Cdc42-ko BMDCs could process OVA equally 
 
Figure 6: Cdc42-ko BMDCs fail to take up soluble antigens, but are capable of OVA processing. 
(A) To target macropinocytosis, receptor-mediated endocytosis and pinocytosis, BMDCs were 
incubated for 20 min with limiting amounts of the fluorescent proteins Alexa-OVA, FITC-dextran 
and Lucifer yellow. Numbers on FACS blots indicate the frequencies of antigen+ cells. Diagrams 
show MFI values gating on CD11c+ cells. Data are from three independent experiments (n=4). (B) 
BMDCs were allowed to take up indicated amounts of Alexa-OVA for three hours and matured 
overnight in the presence of LPS. MFI were obtained gating on CD11c+ cells. Statistics are from one 
experiment with n=2 (wt) and n=3 (Cdc42-ko). (C) BMDCs were incubated with Alexa-OVA and 
DQ-OVA for 15 min. Residual protein was removed from culture supernatants and cells were 
allowed to process DQ-OVA for 15 min. MFI of DQ-OVA were obtained gating on CD11c+Alexa-
OVA+ cells. Data show one experiment (n=2) out of two with similar results.   
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well (Figure 6C) indicating no role for Cdc42 in OVA processing, once the antigen 
has reached the endocytic system of Cdc42-ko BMDCs. 
5.1.4 Cdc42-ko DCs fail to induce proper immune responses to 
OVA-specific T cells 
Antigen presentation requires antigen uptake, processing and MHC loading 
followed by the transport of antigen-bound MHC molecules to the cell surface. 
Once exposed at the plasma membrane, the antigen is presented to antigen-
specific T cells. Since Cdc42-ko BMDCs showed a reduced capacity to capture 
antigens, we investigated MHC I- and MHC II-restricted antigen presentation as a 
functional consequence for this defect.  
To study the presentation of OVA after protein uptake, we pulsed BMDCs with 
indicated concentrations of peptide-free whole OVA protein (Figure 7A). After 
three hours of antigen uptake, we induced maturation of DCs by adding LPS to 
the culture medium. The next day, mature, OVA-loaded BMDCs were co-cultured 
with transgenic T cells that recognize OVA-derived peptides in the context of 
MHC I (OT-I) or MHC II (OT-II). This assay was performed in round-bottom 
plates to overcome possible defects of Cdc42-ko BMDCs in DC:T cell contact 
formation (92, 93). Interestingly, we found that Cdc42-ko BMDCs failed to 
effectively prime both OT-I and OT-II cells (Figure 7A), as concluded from 
frequencies (graphs) of dividing T cells. This result could simply be a direct 
consequence of reduced OVA uptake (see Figure 6A,B). Therefore, we sought to 
overcome the inability of Cdc42-ko BMDCs to take up OVA protein by adding 
pre-processed OVA peptide to mature, LPS-treated cells. These pre-processed 
peptides are readily loaded onto MHC molecules at the cell surface by competing 
for antigens that occupy the binding grooves of MHC molecules. Surprisingly, we 
found that peptide-pulsed Cdc42-ko BMDCs still failed to fully prime OT-I and 
OT-II cells (Figure 7B), as shown for frequencies (graphs) of dividing T cells. These 
results provide evidence that Cdc42 plays a role for both MHC I- and MHC II-
restricted presentation of whole protein antigen and pre-processed antigenic 
peptides, indicating a function of Cdc42 in DC-mediated immune responses. 
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Figure 7: Antigen presentation in the context of both MHC I and MHC II is impaired in Cdc42-
ko BMDCs. 
(A) BMDCs were pulsed with the indicated concentrations of whole OVA protein (peptide-free), 
matured overnight in the presence of LPS and co-cultured with CD8+ and CD4+ OVA-specific 
CFSE-labeled T cells (OT-I or OT-II respectively). After 4 days of co-culture, T cell proliferation was 
determined as CFSE dilution. (B) For peptide presentation, BMDCs received LPS overnight and 
were then incubated with SIINFEKL or P323-339 pre-processed OVA peptides. After 3 hours, 
BMDCs were co-cultured with OT-I or OT-II cells. T-cells were harvested after 3 (OT-I) and 4 (OT-
II) days of co-culture and proliferation was determined as CFSE dilution. (A, B) Diagrams show the 
percentage of divided T cells of one representative experiment carried out in triplicates. 
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5.2 The proteome of Cdc42-ko BMDCs 
5.2.1 An unbiased proteomics screen  
Having identified a role of Cdc42 in antigen presentation, we sought to determine 
factors responsible for the functional differences that occur upon Cdc42 knockout. 
Therefore, we analyzed the whole protein composition (proteome) of wt vs. 
 
Figure 8: Proteomics workflow. 
(I) BMDCs were generated In-house and subjected to proteomics (II). For a detailed description of 
the method, see (4.2.3). In brief, 20 million cells were lysed and proteins denatured using SDS (1). 
After detergent removal in the presence of Urea, Trypsin was used to digest the proteins (2). The 
resulting peptides were fractionated according to their ionic charge by anion-exchange 
fractionation SAX into 5 fractions (3). Two technical replicates of each fraction were measured by 
LC-MSMS (4). Proteins were identified searching a murine IPI database (5) and quantification was 
performed on the basis of unique peptides. (III) Data analysis of proteins identified with at least 4 
unique peptides was performed using the indicated online tools. Expression levels of selected 
proteins in wt vs. Cdc42-ko BMDCs were verified by Western blot or flow cytometry. The 
proteomics (part II of the experiment) were performed by Sebastian Hogl from Stefan 
Lichtenthaler’s group at the DZNE Munich.  
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Cdc42-ko BMDCs by performing an unbiased quantitative proteomics screen.  
The workflow for this experiment is described in Figure 8. In brief, two biological 
replicates of wt and Cdc42-ko BMDCs were lysed and proteins digested using 
Trypsin. Resulting peptides were fractionated according to their ionic charge. Two 
technical replicates of each fraction were measured using a mass spectrometer 
(LC-MSMS) and the identified peptides were assigned to proteins by searching a 
murine IPI database on the basis of unique peptides. Wt and Cdc42-ko samples 
were analyzed separately from each other and resulting data sets were combined 
for label-free quantification as described in chapter 4.2.3.2. The final protein list 
contained fold change values for each identified protein as ratio of Cdc42-ko/wt, 
giving hints about which proteins were up- or downregulated in Cdc42 
knockouts. A total of 2602 proteins could be identified from wt and Cdc42-ko 
BMDCs with a minimum of 4 unique peptides. This list was used for a web-based 
analysis of the data using the online tools shown in Figure 8 and listed in Table 9. 
These web pages contain information about proteins (UniProt), predicted and 
physical protein interactions (String database) and lists of proteins that are known 
to be part of a certain cellular component (the Gene Ontology) or a published 
pathway (KEGG PATHWAY database). Additionally, the screen was evaluated by 
verifying selected proteins that showed an altered abundance in Cdc42-ko 
BMDCs. We used both flow cytometry and Western blot analysis to verify the data 
set. Selected data of this verification procedure will be shown in chapter 5.3. 
5.2.2 Pathways affected upon Cdc42 removal 
To get an idea, which pathways might be affected in Cdc42-ko BMDCs, we first 
globally analyzed this proteomics data set. Therefore, we uploaded all proteins 
with fold change values (Cdc42-ko/wt) <-3.0 (79 proteins) and >+3.0 (475 
proteins) into the String database to generate a network of known and predicted 
protein interactions (Figure 9). A total of 4 of these uploaded proteins were not 
included in this analysis, since they could not be identified by the String database. 
Cdc42 itself was decreased 16-fold, which matched the almost complete absence of 
Cdc42 from total cell lysates, as shown by Western blot in Figure 3B. Using data 
enrichment, the proteins were grouped according to their occurrence in the KEGG 
PATHWAY database, which contains a collection of pathways and associated 
proteins. Figure 9 shows the protein network generated by the String-database 
and lists the eight most affected KEGG entries in this experimental setup, and how 
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many of these 550 up- or downregulated proteins matched the respective KEGG 
entry (indicated by numbers in brackets). Interestingly, many of the identified 
pathways showed a clear connection to Cdc42 function. Furthermore, 5 of the 8 
pathways were directly associated with Cdc42 protein. These KEGG entries were 
(1) Regulation of actin polymerization, (2) Endocytosis, (3) Mitogen-activated 
protein kinase (MAPK) signaling pathway, (4) Pathways in cancer and (5) 
Adherens junctions. Other pathways like Phagosome and Lysosome did not match 
Cdc42 itself, but proteins affected upon Cdc42 removal. Thus, removing Cdc42 
from equation seemed to severely affect the lysosomal compartment of DCs, 
providing evidence for a previously unknown regulatory role of Cdc42 in 
maintaining lysosomal integrity. Table 10 provides a complete list of up- or 
downregulated proteins that matched the respective KEGG pathways. 
 
 
Figure 9: Pathways affected upon Cdc42 removal. 
The diagram shows known and predicted interactions of proteins that were more than 3-fold up- 
or downregulated in Cdc42-ko as compared to wt BMDCs, and was generated using the String 
database (www.string-db.org). Each node represents one protein, lines represent direct binding of 
proteins (blue), catalysis (purple) or reactions (black). The 8 most abundant KEGG pathways were 
determined by data enrichment, which highlights the proteins that are listed in the above 
mentioned pathways in the KEGG database (http://www.genome.jp/kegg/pathway.html). For 
simplicity, only total numbers of input proteins matching the indicated pathways are shown in the 
figure. A full protein list is provided in Table 10 (see below). Pathways marked with an asterix 
include Cdc42. 
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Table 10: Differentially regulated proteins in Cdc42-ko BMDCs matching the respective KEGG 
PATHWAY entry. 
Proteins were clustered by the String-database according to their occurrence within the respective 
KEGG pathway. Proteins are listed according to their gene names in alphabetical order. For more 
information on single proteins, see www.uniprot.org (search: gene name and mus musculus), for 
their occurrence and function in the respective pathway see 
http://www.genome.jp/kegg/pathway.html. 
 
5.2.3 Cdc42-ko DCs show abnormities in lysosomal protein 
composition   
The finding that the lysosome of DCs was affected upon removal of Cdc42 
encouraged us to analyze the proteomics dataset with respect to lysosomal protein 
composition. The nature of the lysosome is crucial for antigen presentation since it 
contains proteases that degrade antigens and are involved in Ii processing and 
thus MHC II loading.  
We used the Gene Ontology (GO) web site to obtain a complete list of proteins 
associated with the cellular component lysosome (GO:0005764). Of the 232 
proteins listed under this term (as of September 2012), 82 could be identified in 
our screen. Of those 82 proteins, almost half (46 %) were more than 2 fold up- or 
downregulated in the absence of Cdc42. These changes in lysosomal protein 
composition were striking as compared to other GO terms analyzed in this 
Pathway (KEGG entry) Differentially regulated proteins 
  
Phagosome Atp6v1e1, Atp6v1h, Cd14, Cd36, Ctsl, Cyba, Cybb, Lamp1, M6pr, 
Mrc1, Sec22b, Tap1, Tap2, TLR2, TUBB5 
Lysosome Acp5, Ap1b1, Asah1, Atp6v1h, Ctsb, Ctsl, DNAse2a, Fuca1, Glb1, 
Igf2r, Lamp1, Lipa, M6pr, Man2b1 
Ubiquitin mediated 
proteolysis 
Birk6, Cblb, Cdc23, Cul4a, Fbxo2, Itch, Keap1, Nedd4l, Ppil2, Syvn1, 
Ube2k, Ube4a, Wwp1 
Regulation of the actin 
cytoskeleton 
Baiap2, Cd14, Cdc42, Dock1, Egfr, Git1, Itgal, Itgax, Pak1, Pik3cg, 
Rac2, Scin, Tiam1, Wasf2 
Endocytosis Apa2a2, Arfgap1, Arfgap2, Arrb1, Cblb, Cdc42, Egrf, Git1, Itch, 
Nedd4l, Psd4, Smap1, Wwp1 
MAPK signaling pathway Arrb1, Cd14, Cdc42, Egfr, Map3k14, Mapkapk3, Mef2c, Pak1, 
Pla2g4a, Prkaca, Ptpn7, Rac2, Rps6ka4 
Pathways in cancer Cblb, Cdc42, Cdh1, Cdk2, Ctnna1, Ctnnb1, Egfr, Kitl, Pik3cg, Rac2, 
Rb1, Traf1 
Adherens junctions Baiap2, Cdc42, Cdh1, Csnk2b, Ctnna1, Ctnnb1, Ctnnd1, Egfr, Fbxo2, 
Ftprj, Wasf2 
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manner. A complete list of proteins that matched the GO term lysosome is 
provided in the Appendix (Chapter 7.1, Table 11).  
While analyzing the GO term lysosome, we realized that besides the classical 
lysosomal proteins Lamp1 and Lamp2, many cathepsins were downregulated 
upon Cdc42 knockout (Figure 10). Interestingly, two of those, Cathepsin L (Ctsl) 
and Cathepsin S (Ctss), have roles for invariant chain (Ii) degradation and 
therefore MHC II loading. However, besides changes in the GO term lysosome 
there were also substantial changes in the GO term actin-binding proteins. Three 
interesting proteins with roles for actin-branching (Flna; Filamin a), filament 
capping (Capza1; F-actin capping protein subunit alpha1) and filament-severing 
(Scin; Adseverin) properties showed altered levels. Also, microtubule-binding 
proteins that play a role for actin-based cell motility (Myh10; Myosin heavy chain 
IIb), microtubule stability (Stmn; Stathmin) and microtubule assembly (Map4; 
Microtubule-associated protein 4) were affected. However, there were virtually no 
changes in MHC II (H2-Aa) expression and only a slight increase in the expression 
of the H2-M chaperone (H2-DMa/b), which functions in CLIP exchange for the 
antigenic peptide. Cdc42, which was decreased approximately 16-fold, is shown as 
positive control for the screen and Gapdh served as housekeeping protein with a 
normal, Cdc42-independent expression (Figure 10). 
                
Figure 10: Selected differentially regulated proteins in Cdc42-ko BMDCs . 
The bar graph shows fold change values (Cdc42-ko/wt) ± SEM of selected proteins that belong to 
the lysosomal compartment, have actin- or microtubule- (MT) binding properties, or are associated 
with  the MHC II pathway. Proteins marked with an asterix could not be detected with a minimum 
of 4 unique peptides. Data are depicted on a log2-scale. 
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5.3 Cdc42 controls invariant chain (Ii) processing and thus, 
MHC II loading in an actin-dependent manner  
Having performed these analyses we next sought to identify the mechanism by 
which Cdc42 controls MHC II antigen presentation. We have shown that Cdc42-
deficient DCs, fail to present pre-processed OVA peptide in the context of MHC II 
(Figure 7B) despite of normal MHC II expression at the cell surface (Figure 4). 
Given the changes in lysosomal protein composition identified by the proteomics 
screen, we asked whether MHC II loading was functional.  
5.3.1 Confirmation of the proteomics screen: Cdc42-ko DCs lack 
lysosomal proteases 
To validate the proteomics screen, we performed Western blot analysis for 
selected lysosomal proteins. LAMP-1 (Lysosome-associated membrane 
glycoprotein 1) is present at lysosomal membranes and commonly used as a 
marker for late-endosomal/lysosomal compartments. Cathepsin D (Ctsd) is an 
aspartic protease that functions for protein breakdown in lysosomes, but in 
contrast to LAMP-1 is a soluble protein. Ctss and Ctsl are both cysteine proteases 
with high similarity, which can compensate for each other’s loss to some extend 
(39). Both are active in lysosomes and especially Ctss has interesting functions for 
the processing of the invariant chain chaperone (Ii) that occupies the MHC II 
binding groove prior to antigen loading.  
As shown in Figure 11A, the lysosomal proteins LAMP-1, Ctss, Ctsl and Ctsd were 
detected at very low amounts in Cdc42-ko BMDCs (Figure 11A). Interestingly, 
even the precursor forms of Ctsl and Ctsd, detected as higher molecular weight 
bands, were virtually absent in cells lacking Cdc42. This detail indicates that 
maturation of both Ctsl and Ctsd was not affected by the loss of Cdc42, as soon as 
their precursors entered the endocytic system. Low expression of LAMP-1 in 
Cdc42-ko cells was additionally confirmed by intracellular FACS analysis 
(Figure 11B). We tested, if the expression of these lysosomal proteins was normal 
at mRNA level, and performed qPCR from wt vs. Cdc42-ko BMDCs. We detected 
a non-significant reduction of LAMP-1, Ctsl and Ctsd mRNA in Cdc42-ko BMDCs, 
whereas the expression of Ctss mRNA was normal (Figure 11C). These data 
provide evidence that the Cdc42-dependent regulation of lysosomal protein 
contents most likely occurs at the protein level. 
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5.3.2 The lack of Cathepsin S in Cdc42-ko BMDCs causes an 
MHC II loading defect by inhibiting Ii processing 
Having shown that Cdc42-ko BMDCs express low levels of lysosomal enzymes 
including Ctss, we wondered whether MHC II loading was functional. MHC II 
occupied by Ii travels from the ER either directly to the MIIC, or via the plasma 
membrane. Therefore, Ii occupies a small portion of MHC II at the plasma 
membrane. This protein complex can be detected using an antibody (clone 15G4) 
that recognizes Ii in the context of MHC II with high affinity for the p12 fragment 
and low affinity for the p31 and p41 fragments of Ii.  
We stained wt and Cdc42-ko BMDCs for surface-Ii and analyzed both groups by 
flow cytometry. Surprisingly, we could detect high levels of Ii at the cell surface of 
Cdc42-ko BMDCs (Figure 12A). Furthermore, Ii surface expression increased on 
 
Figure 11: Cdc42-ko BMDCs lack lysosomal proteins, which are expressed at normal amounts on 
mRNA level. 
(A) BMDC total cell lysates were analyzed by Western blot using specific antibodies for LAMP-1 
and Cathepsin S, L and D. Actin was used as loading control. Each Western blot shows one 
representative out of at least three independent experiments. (B) Intracellular FACS analysis on 
fixed and permeabilized BMDCs confirms a downregulation of LAMP-1 protein. MFI are depicted 
as relative to wt gating on CD11c+ cells. The histogram shows pooled data from two independent 
experiments (n=3). (C) mRNA expression of all lysosomal proteins shown in (A) was measured by 
qPCR. Data are from a single experiment carried out in triplicates. 
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both wt and Cdc42-ko cells upon maturation, indicating that immature DCs 
possessed a large pool of intracellular Ii-bound MHC II that appeared only in 
parts at the plasma membrane. Next, we calculated a ratio between the MFI of Ii-
bound MHC II (MFI clone 15G4) and total MHC II (MFI clone AF6-120.1,) and 
found that unstimulated as well as mature Cdc42-ko BMDCs expressed 
approximately 2-fold higher amounts of 15G4 epitopes relative to total MHC II 
epitopes (Figure 12B). 
In immature DCs, Ii-bound MHC II molecules are quickly internalized from the 
plasma membrane and transported to MIICs. Therefore, we assessed 
internalization of Ii-bound MHC II, as a possible reason for its accumulation at the 
plasma membrane (Figure 12C). BMDCs were labeled for surface-Ii using 
antibody clone 15G4 (T=0) and internalization of the antibody was assessed after 
indicated times by detection of remaining antibody. Interestingly, Cdc42-ko 
BMDCs showed a much slower internalization rate of Ii as compared to wt cells, 
indicating that the expression of Ii-bound MHC II is stabilized at the cell surface of 
DCs in a Cdc42-dependent manner. However, also total MHC II was stabilized on 
the cell surface of Cdc42-ko BMDCs in a similar manner (data not shown), 
indicating a role of Cdc42 in MHC II trafficking as a general phenomenon upon 
Cdc42 knockout. 
 
Figure 12: Cdc42-ko BMDCs accumulate Ii-occupied MHC II molecules at the cell surface. 
(A) BMDCs were stained for total cell surface MHC II and 15G4 epitopes and analyzed by flow 
cytometry. Mature BMDCs were generated by overnight LPS treatment. (B) MFI values obtained 
from (A) were used to calculate the ratio of Ii-bound MHC II (clone 15G4) to total surface MHC II 
(clone AF6-120.1), which gives an indication about how much MHC II is occupied by Ii in wt vs. 
Cdc42-ko BMDCs. Bar graphs show one representative experiment out of 10 with 2 biological 
replicates. (C) Internalization of the 15G4 antibody was measured by detection of remaining 15G4 
antibody at the indicated times. The graph shows relative fluorescence intensity (rFI) values on 
CD11c+ cells as percentages of time zero. Data are from pooled experiments. 
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Having shown that Ctss is present at low concentrations (Figure 11A) and that Ii 
accumulates at the cell surface of Cdc42-ko BMDCs (Figure 12), we wondered 
whether Ii processing was functional in the absence of Cdc42. Figure 13A (94) 
summarizes Ii processing and the proteases involved. In brief, Ii processing 
proceeds from C-terminal to N-terminal direction along the endocytic route, 
including non-cysteine (purple fond) and cysteine (green fond) proteases. The 
non-cysteine protease asparagine endopeptidase (AEP) mediates the first 
processing step by degrading the 31kDa intermediate p31 of Ii (also expressed as 
41kDa isoform p41) into a 22kDa fragment p22, which is then rapidly transformed 
into a 10kDa degradation intermediate p10 (also expressed as 12kDa isoform p12). 
Ii-p10/12 is the smallest fragment of Ii that still comprises its transmembrane 
domain and is further processed into CLIP. According to the literature Ctss 
conducts the final step of Ii-p12 degradation in DCs, separating the CLIP fragment 
at the luminal part of the protein, which occupies the MHC II binding groove, 
 
Figure 13: The Ii degradation intermediate p12 accumulates in Cdc42-ko BMDCs. 
(A) Model of Ii processing published by Colin Watts, 2004 (94). For description, see text. (B) BMDC 
total cell lysates were analyzed by Western blot using a specific antibody for Ii  (clone ln-1) that 
recognizes a 41 and a 31kDa isoform as well as a 12kDa processing intermediate of Ii (termed p41, 
p31 and p12 of CD74). Actin was used as loading control. Bar graph shows a quantification of the 
Western blot (n=2). (C) To look at Ii message, RNA was isolated from unstimulated wt and Cdc42-
ko BMDCs and qPCR was performed using CD74 specific primers. Relative expression levels of 
CD74 mRNA are from three combined experiments, each with a minimum of two mice per group. 
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from its transmembrane domain. 
To study Ii degradation at the protein level, we used a CD74 antibody (clone ln-1) 
that recognizes an epitope at the short N-terminal part of the Ii chaperone that 
faces the cytoplasm. Hence, the antibody recognizes all forms of Ii that still include 
the transmembrane domain, namely the p41, p31 and p12 degradation 
intermediates of Ii.  
Indeed, we could detect all above mentioned degradation intermediates of Ii in 
total cell lysates from wt and Cdc42-ko BMDCs (Figure 13B). Notably, wt BMDCs 
expressed high amounts of 41 and 31kDa isoforms, whereas the 12kDa fragment 
was present at low abundance, due to its rapid degradation. In Cdc42-ko BMDCs, 
on the other hand, the 12kDa fragment accumulated more than three fold as 
compared to wt cells. This Ii degradation arrest in Cdc42-ko BMDCs would be in 
agreement with reduced Ctss levels in these cells as shown in Figure 11A. To 
exclude a regulation of Ii (CD74) expression on the mRNA level, we performed 
qPCR on total RNA from wt vs. Cdc42-ko BMDCs and found Ii message expressed 
at normal amounts (Figure 13C). This finding supports our interpretation that 
Cdc42-dependent Ii processing is regulated on the protein level. 
5.3.3 Functional actin dynamics are required for both lysosomal 
integrity and Ii degradation  
We have shown that Cdc42 controls the expression of lysosomal proteases 
(Figure 11A,B) with effects on Ii degradation (Figure 13B) and MHC II loading 
(Figure 12). Ii-occupied MHC II molecules at the cell surface of Cdc42-ko BMDCs 
possibly hinder the presentation of pre-processed OVA peptides to OT-II cells 
(Figure 7B and Figure 12). However, the mechanism by which Cdc42 controls 
these processes remains unclear. Therefore, we studied actin and microtubule 
dynamics as well as endosomal acidification with respect to intracellular protease 
levels and Ii degradation.  
Our approach was to target wt BMDCs with inhibitors that (i) globally inhibit 
actin polymerization through their direct interaction with the actin filament, (ii) 
inhibit microtubule dynamics or (iii) inhibit endosomal acidification. 
Latrunculin B (LatB) binds G-actin forming a 1:1 molar complex, thereby 
preventing monomers from re-polymerizing into filaments. Cytochalasin D 
(CytD), on the other hand, inhibits actin polymerization by capping filaments at 
their plus, fast growing barbed ends in a 1:1 stoichiometry. To discriminate 
CDC42 AND MHC II LOADING 
 
 54 
between actin and microtubule dynamics, Nocodazole (Noco) was used as a 
microtubule-disrupting drug, which binds to both free and assembled tubulin 
causing conformational changes. Concanamycin B (ConB) was used to inhibit the 
V-ATPase proton pump, which is required for proton translocation into the vesicle 
and therefore endosomal acidification (see also Figure 14). 
We treated BMDCs with these inhibitors overnight and looked for cell surface-Ii 
expression using antibody clone 15G4. Upon direct actin inhibition by either LatB 
or CytD, large amounts of both MHC II and Ii-bound MHC II (15G4) were 
transported to the cell surface of wt BMDCs, which resulted in an accumulation of 
MHC II molecules at the cell surface (Figure 15A, left panel). As for Cdc42-ko 
BMDCs (Figure 12B) we calculated the amount of Ii-bound MHC II as a ratio 
relative to total cell surface-MHC II expression of inhibitor-treated cells. 
Interestingly, specifically actin disruption, but not the inhibition of microtubules 
or V-ATPase mediated acidification of endosomes lead to an accumulation of Ii at 
the cell surface of wt BMDCs (Figure 15A, right panel). 
 
Figure 14: Inhibitors used to disrupt actin, microtubules and endosomal acidification and modes 
of action. 
All above mentioned inhibitors are small molecules and freely permeable through cell membranes. 
For description, see text. Mechanisms of Latrunculin B (A) and Cytochalasin D (B) modes of action 
are based on Morton et al., 2000 (79) and John A. Cooper, 1987 (78) respectively. (C) Microtubule 
scheme is adapted from Conde & Caceres, 2009 (95). (D) V-Atpase functions were described by 
Michael Forgac (96). 
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DCs react strongly upon treatment with minimal doses of LPS or other bacteria-
derived stimuli, which unfortunately often contaminate solutions. To exclude the 
possibility that the observed upregulation of MHC II on inhibitor-treated DCs 
simply represented a mature phenotype as a result of inhibitor-treatment, we 
analyzed BMDC supernatants for pro-inflammatory cytokines (Figure 16A); 
culture supernatants from LPS-treated BMDCs served as positive control. 
However, inhibitor-treated wt BMDCs neither showed elevated levels of pro-
 
Figure 15: MHC II loading and processing are impaired upon actin inhibition in wt BMDCs. 
(A) Wt BMDCs were incubated with the actin inhibitors LatB and CytD overnight or left untreated. 
The next day, total surface MHC II (clone AF6-120.1) and Ii bound to MHC II (clone 15G4) were 
analyzed by flow cytometry. The effects of V-ATPase inhibitor ConB and microtubule inhibitor 
Noco were also analyzed in this manner. Analysis was done gating on CD11c+CD86LO cells (not 
shown). Bar graphs show the ratio of MFI 15G4/total surface MHC II of one representative 
experiment out of 3 (n=2). (B) Wt BMDCs were treated with inhibitors as mentioned in (A) and total 
cell lysates were analyzed by Western blot. Membranes were probed for Cathepsin L, Cathepsin S 
and Ii (CD74). Tubulin served as loading control. Bar graphs show a quantification of protein 
expression levels from two independent experiments (n=2) normalized to actin or tubulin. (C) 
Internalization of the 15G4 antibody in untreated vs. CytD-treated wt BMDCs was assessed by 
detection of remaining antibody at the indicated times. The graph shows relative fluorescence 
intensity (rFI) values on CD11c+ cells as percentages of time zero from pooled experiments. 
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inflammatory cytokines nor an increase in mRNA expression of CD86 and CD40 
(Figure 16B), indicating that the upregulation of MHC II at the cell surface was not 
due to DC maturation, but specifically due to the inhibition of the actin 
cytoskeleton. 
Next, we looked at Ii processing and intracellular Ctss and Ctsl expression by 
Western blot on inhibitor-treated wt BMDCs. We observed an accumulation of the 
smallest 12kDa fragment of Ii, similar to what was observed in DCs that lacked 
Cdc42 (Figure 15B and Figure 13B). Furthermore, actin inhibition lead to a 
substantial reduction of both Ctss and Ctsl levels from total cell lysates of 
inhibitor-treated wt BMDCs. Interestingly, also these effects could be dedicated 
specifically to the actin cytoskeleton, since disruption of microtubules using Noco 
did not show an effect. However, inhibition of V-ATPase using ConB also 
 
Figure 16: Treatment with actin inhibitors does not induce maturation of BMDCs. 
(A) To exclude an effect on DC maturation, supernatants of wt DCs pulsed with LatB or CytD were 
analyzed using a cytometric bead array (CBA, Mouse Inflammation Kit). Supernatants were tested 
for pro-inflammatory cytokines; LPS-treated culture supernatants served as positive control. Bar 
graphs show one of two independent experiments carried out in duplicates. (B) mRNA 
transcription of co-stimulatory molecules was assessed to exclude the possibility that inhibitor 
treatment activates BMDCs. RNA from unstimulated and inhibitor-treated cells was isolated and 
CD86 and CD40 mRNA expression was analyzed by qPCR. HPRT was used as housekeeping gene. 
Data are from two experiments (n=4). 
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significantly increased p12 expression in inhibitor-treated wt BMDCs, which 
indicates that endosomal acidification might also be relevant for Ii degradation.  
In immature DCs, Ii-bound MHC II is efficiently internalized from the plasma 
membrane by endocytosis and targeted to the MIIC. Inhibition of actin dynamics 
could thus, similar to the loss of Cdc42 from cells (see Figure 12C), lead to a 
retention of Ii at the plasma membrane. To evaluate, whether the surface 
accumulation of Ii upon actin inhibition was due to a decreased internalization 
rate of Ii-bound MHC II molecules, we tested the internalization of the 15G4 
antibody and found that it was indeed stabilized on the cell surface of CytD 
treated wt cells (Figure 15C).  
From this series of experiments we concluded that functional actin dynamics were 
definitely required for both Ii re-internalization from the plasma membrane and 
lysosome biogenesis as a prerequisite for functional Ii processing. 
 
Since lysosomal proteins were present at low amounts in Cdc42-ko BMDCs and 
disappeared from wt cells upon actin inhibitor-treatment, we sought to determine 
the reason for this loss of lysosomal contents from cells that lacked Cdc42, or cells 
treated with actin inhibitors. One possibility of regulating intracellular protease 
content is secretion. Therefore, we wanted to know whether actin inhibition 
caused secretion and we tested if secreted proteins were detectable in the 
supernatant. 
To evaluate Ctsl levels in culture supernatants, equal amounts of protein were 
analyzed because this method lacks a loading control. Medium served as negative 
control and signals were quantified relative to supernatants from untreated wt 
BMDCs. As shown in Figure 17A actin inhibition by LatB and CytD indeed lead to 
an accumulation of mature Ctsl in culture supernatants, whereas ConB and Noco 
treatment did not show an effect. Notably, also maturation of BMDCs using LPS 
did not alter extracellular Ctsl levels significantly (data not shown), indicating that 
the export of Ctsl was maturation-independent.  
We used Western blot data from total cell lysates and supernatants and calculated 
the fold secretion of total mature Ctsl contents, which visualizes the imbalance of 
intra- and extracellular Ctsl levels upon actin inhibition or Cdc42 knockout 
(Figure 17B). CytD treatment of wt cells lead to an approximately 14-fold increase 
in secretion of total mature Ctsl contents. The same tendency was observed for 
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untreated Cdc42-ko BMDCs, which secreted approximately three times more Ctsl 
as compared to untreated wt BMDCs (Figure 17B).  
These results provide evidence that upon direct actin inhibition by LatB or CytD, 
DCs translocate mature Ctsl into culture supernatants, possibly as a default 
pathway. By treating DCs with actin inhibitors, we could therefore induce a 
phenotype similar to untreated Cdc42-deficient DCs. However, it may be noted 
here that Cdc42-deficient BMDCs showed a downregulation of lysosomal protein 
levels including Ctsl already in the steady-state (Figure 11A and B), whereas wt 
cells bore full stores of these proteins that could be secreted upon actin inhibition. 
Thus, inhibitor treated wt as well as untreated Cdc42-ko BMDCs both might 
secrete the amount of Ctsl at their disposal, which could explain the differences in 
the secretion of total Ctsl contents (Figure 17B). 
 
5.3.4 Cdc42 acts via the Arp2/3 complex on the actin cytoskeleton, 
with no impact on Ii processing 
Having shown in the previous chapter that global inhibition of the actin 
cytoskeleton had an impact on MHC II loading, we next wanted to investigate the 
mechanism Cdc42 might use to control actin dynamics. We used previously 
published inhibitors targeting protein complexes that, via Cdc42, lead to changes 
in the actin network. Figure 18 summarizes these inhibitors and their mode of 
action. In brief, CK-548 inhibits the Arp2/3 complex required for the branching of 
actin filaments. SMIFH2 inhibits a formin dimer important for the linear 
polymerization of filaments. Both CK-548 and SMIFH2 are drugs that inhibit 
 
Figure 17: Upon actin inhibition, lysosomal contents are secreted into culture supernatants. 
(A) Culture supernatants of inhibitor-treated wt BMDCs were analyzed by Western blot for Ctsl 
secretion. For this purpose, equal amounts of protein were loaded; medium was used as negative 
control. Bar graphs show a quantification of protein expression levels from one representative 
experiment (n=2) normalized to wt untreated. (B) Bar graphs show fold secretion of total 20kDa 
Cathepsin L (mature Ctsl) content taking into account intracellular and extracellular Ctsl. One 
representative experiment out of at least three with n=2 is shown.   
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complexes downstream of Cdc42 signaling required for functional actin dynamics. 
The inhibitor Gö 6983, on the other hand, inhibits PKCα signaling upstream of 
Cdc42, which leads to an arrest of Cdc42-dependent podosome formation. 
Figure 19A shows a titration of the Arp2/3 inhibitor CK-548 on wt BMDCs and its 
impact on Ii-bound MHC II complexes at the cell surface of these cells. Also the 
effects of SMIFH2 and Gö 6983 were analyzed in this manner. Upon treatment 
with the highest concentration of CK-548 over 80 % of cells died (gate R1). By 
gating on DAPI-CD11c+ cells (gate R2) we could detect a slight upregulation of Ii at 
the cell surface using a high dose of CK-548, but this phenotype was modest as 
compared to unstimulated Cdc42-ko BMDCs (Figure 12). However, the effect was 
significant (Figure 19A), even though we could not observe a titration effect at 
lower concentrations of the inhibitor. The inhibitors SMIFH2 and Gö 6983 did not 
influence surface-Ii expression on wt BMDCs (Figure 19A). Furthermore, the 
treatment of wt BMDCs with CK-548, SMIFH2 or Gö 6983 had neither an effect on 
Ii processing nor intracellular protease expression, as observed by analyzing total 
cell lysates for the expression of Ii (CD74 p41, p31, p12) and Ctsl by Western blot 
(Figure 19B). Due to dead cell contents in lysates at the highest concentration of 
CK-548 the signal obtained could not be quantified (Figure 19B, second lane).  
We next investigated culture supernatants of inhibitor-treated cells for 
extracellular Ctsl and found that specifically the mature form of Ctsl accumulated 
upon CK-548 treatment (Figure 19C). Ctsl precursor protein, which was expressed 
 
Figure 18: Inhibitors used to target Cdc42-dependent actin polymerization and modes of action. 
(A) The Arp2/3 complex is required for the branching of actin filaments. CK-548 inhibits Arp2/3 
binding to filaments and therefore filament branching. (B) Formins surround actin filaments at their 
plus end, thereby preventing binding of capping proteins. SMIFH2 inhibits the formin FH2 dimer 
required for a linear growth of the filament. (C) Protein kinase C (PKCα) signaling is required for 
Cdc42-dependent podosome formation. The complex can be inhibited using Gö 6983. CK-548 and 
SMIFH2 target processes downstream of Cdc42, whereas Gö 6983 inhibits an upstream signaling 
cascade. All inhibitors are small molecules that are freely permeable through cell membranes. (A) 
and (B) were adapted from Campellone and Welch, 2010 (97). Model (C) was adapted from Tatin et 
al., 2006 (59). 
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at stable amounts upon inhibitor treatment, constitutes an internal control 
excluding an influence of dead cell contents on extracellular Ctsl levels. 
Furthermore, we could detect a titration effect for secretion of mature Ctsl that 
mirrors CK-548 titration. The inhibitors SMIFH2 and Gö 6983 showed no effect on 
Ctsl secretion (Figure 19C). We concluded that specifically Arp2/3-mediated actin 
disruption resulted in an enhanced secretion of mature Ctsl (Figure 19B) and an 
upregulation of surface-Ii expression at the highest concentration of CK-548 
(Figure 19A, right bar graph). 
 
 
Figure 19: Inhibition of the Arp2/3 complex has an impact on  surface-Ii expression and 
influences Ctsl secretion. 
(A) Wt BMDCs were treated with the indicated concentrations for CK-548, SMIFH2, Gö 6983 or left 
untreated. Analysis was done by flow cytometry based on DAPI staining for dead cell exclusion 
and surface-Ii expression (Ratio MFI 15G4/MHC II), the latter gating on DAPI-CD11c+ cells. Bar 
graphs show two experiments (CK-548, n=4; SMIFH2, n=3) and three experiments (Gö 6983, n=6) 
with similar results. (B) Total cell lysates of inhibitor-treated wt BMDCs were analyzed for 
Cathepsin L and Ii (CD74) expression by Western blot. Gapdh served as loading control. One 
representative experiment out of two is shown. (C) Supernatants of inhibitor-treated wt BMDC 
cultures were analyzed by Western blot for Cathepsin L secretion. Medium served as negative 
control and signals were quantified relative to wt untreated. Bar graph shows one representative 
experiment (n=2) out of two with similar results.  
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5.3.5 BMDCs defective for clathrin-mediated vesicle budding 
secrete mature Ctsl into culture supernatants 
Soluble lysosomal proteases exit the Golgi apparatus via clathrin-coated pits that 
bud off the trans-Golgi network (TGN) in an Arp2/3- and actin-dependent 
manner (26, 27). Therefore, we wondered whether clathrin-mediated vesicle 
budding played a role for Ctsl secretion.  
We used the recently published inhibitor Pitstop 2, which inhibits clathrin-
mediated endocytosis at the plasma membrane and possibly clathrin-dependent 
vesicle budding at the TGN (82). Interestingly, we observed that Pitstop 2-treated 
wt BMDCs secreted elevated amounts of mature Ctsl as compared to untreated wt 
cells, as shown by Western blot on inhibitor-treated culture supernatants 
(Figure 20). A quantification of both precursor and mature Ctsl protein expression 
visualized that predominantly the mature form of the protease was secreted- 
similar to what we observed upon Arp2/3 inhibition of wt cells (Figure 19C, 
Figure 20). However, there was no effect on either cell surface expression of Ii-
bound MHC II, or Ii processing and intracellular protease levels (data not shown), 
which is therefore a rather mild phenotype with respect to MHC II loading as 
compared to the direct inhibition of actin (Figure 15B).  
Clathrin coated pits and vesicles also contain Hip1r, which is thought to be a 
linker protein between the endocytic machinery and the actin cytoskeleton. 
Figure 21A (taken from (26)) shows the protein composition at clathrin coated 
vesicles (CCV) at both the plasma membrane and the TGN including actin 
nucleating and actin binding factors. In brief, F-Bar binding proteins (FCHo) 
 
Figure 20: Clathrin inhibition leads to an accumulation of mature Ctsl in culture supernatants. 
Wt BMDCs were treated with the indicated concentrations of Pitstop 2, an inhibitor for clathrin-
mediated endocytosis, and supernatants were analyzed for Cathepsin L secretion by Western blot. 
Signals obtained from Western blot were quantified relative to wt untreated. Bar graph shows 
combined data of two independent experiments with similar results (n=3). 
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initially deform the membrane and, like clathrin, bind actin-nucleating factors. 
One of the proteins that connects the emerging vesicle with pre-existing F-actin 
filaments is Hip1r. Also, this protein might prevent actin polymerization at the 
coat surface of the vesicle and dissociate upon vesicle budding. Therefore, Hip1r 
might function as a negative regulator of vesicle scission. In order to release the 
vesicle from membranes actin nucleating factors like F-Bar domain proteins 
(BDPs), N-Wasp, Cdc42 and Arp2/3 provide the mechanical force to bend and 
push membranes. 
To find out, whether Hip1r expression is affected upon Cdc42 knockout, we 
examined Hip1r protein expression in Cdc42-ko BMDCs (proteomics: 4.6±1.64 fold 
change Cdc42-ko/wt±SEM; ≥2 unique peptides). Interestingly, Hip1r was slightly 
upregulated in the absence of Cdc42, although not to an extent that was 
statistically significant (p=0.0732, n=4; Figure 21B). However, we concluded that 
vesicle coat components at both the plasma membrane and the TGN could be 
regulated in a Cdc42-dependent manner and might add up to their poor ability to 
provide functional vesicle transport. 
 
Figure 21: Hip1r is slightly upregulated in Cdc42-ko BMDCs. 
(A) Model of clathrin carrier biogenesis at the plasma membrane (a) and the trans-Golgi network 
(b). For description see text. Figure from Anitei & Hoflack, 2012 (26) (B) Total cell lysates of wt and 
Cdc42-ko BMDCs were analyzed for the expression of Hip1r protein by Western blot; Gapdh 
served as loading control. The bar graph shows results from two experiments (n=4). The difference 
in protein expression was not significant (p=0.0732). 
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5.3.6 Summary of processes affected upon Cdc42 knockout with 
implications for MHC II loading 
In this chapter we provided evidence that Cdc42, possibly via its interaction with 
the actin cytoskeleton, interferes with lysosomal protease targeting to late 
endosomes. The inability to generate functional late endosomal compartments 
results in defective Ii processing and Ii-occupied MHC II molecules. 
In brief, we showed that Cdc42-ko BMDCs failed to acquire sufficient amounts of 
antigens to induce proper immune responses. Furthermore, the composition of 
late endosomes was altered, resulting in a degradation arrest of Ii. Hence pre-
occupied MHC II molecules accumulated at the plasma membrane as a result of 
their decreased re-internalization. This stabilization at the cell surface was actin-
dependent, as was protease targeting to late endosomes, where Ii processing takes 
place. Altogether we describe a previously unknown role of Cdc42 that in an 
actin-dependent manner affects MHC II loading. 
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5.4 Phenotype of Cdc42-ko mice 
5.4.1 DC subsets in spleen and lymph nodes of Cdc42-ko mice 
The availability of Cdc42-ko mice gave us the possibility to study Cdc42 function 
in vivo. As described in our publication (Paper I) especially migratory DCs isolated 
from different organs of mice were strongly affected upon Cdc42 knockout. I 
would like to refer to the original publication for further detail on the migration of 
Langerhans cells, but will mention here selected findings published in this paper 
that are important for the current subject: 
Spleen DCs were present at both normal frequencies and numbers in Cdc42-ko 
mice as compared to wt mice (Paper I, Supplementary Figure S1A), which also 
applied when CD8+ and CD8- DC subsets were analyzed separately from each 
other (data not shown). The knockout in purified spleen DCs, analyzed as a 
representative in vivo DC subset, was not complete as judged from residual Cdc42 
protein detected by Western blot (Paper I, Supplementary figure S1D). However, 
these cells were already devoid of functional Cdc42 mRNA (data not shown), 
indicating that their lifespan might be not long enough in order to metabolize 
100 % of remaining Cdc42 protein. 
In contrast, in skin-draining lymph nodes we observed substantial changes. Both 
frequencies and numbers of CD11c+MHC IIHI migratory DCs were dramatically 
reduced (***p<0.0001), whereas CD11c+MHC IIIM resident DCs, represented in 
significantly elevated frequencies (*p=0.0189), seemed to compensate for this loss 
to some extend (Paper I, Figure 1A).  
 
In order to investigate, if there is a similar contribution of Cdc42 to MHC II 
loading in DCs in vivo, we investigated P323-339 peptide presentation in spleens 
and Ii expression on both spleen and lymph node DCs from Cdc42-ko as 
compared to wt mice. 
5.4.2 Antigen presentation of OT-II peptide is impaired in vivo 
In previous chapters, we clearly identified a role of Cdc42 in MHC II antigen 
presentation in DCs using in vitro generated BMDCs. However, we had an animal 
model at hand that allowed us to study the function of Cdc42 in vivo.  
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We started our investigation with a transfer of a single dose of P323-339 peptide 
plus LPS to wt and Cdc42-ko mice that had received OT-II cells the previous day. 
Five days after immunization, spleens of immunized mice were analyzed for 
transgenic T cells. CD4+CD90.1+ transferred OT-II cells were clearly present at both 
reduced frequencies and numbers in spleens from immunized Cdc42-ko mice 
(Figure 22A), indicating defective CD4+ T cell stimulation by Cdc42-ko DCs in vivo. 
Downregulation of CD62L and up-regulation of CD44 were used as markers for 
T cell activation. Interestingly, CD90.1+ OT-II cells in Cdc42-ko mice were less 
activated (Figure 22B), as indicated by a reduced downregulation of CD62L. 
However, CD44 upregulation was normal on OT-II cells isolated from immunized 
Cdc42-ko mice, indicating that the activation of T cells was probably delayed in 
these mice. 
 
Figure 22: Cdc42-ko mice exhibit an impaired T cell response upon P323-339 peptide transfer. 
(A) CD4+ OT-II cells (CD90.1+) were enriched by negative selection and transferred into wt or 
Cdc42-ko mice. The next day, mice were challenged with a single dose of LPS plus P323-339 
peptide, or LPS alone (no peptide control). Spleens were harvested after five days and T cells were 
analyzed based on the expression of CD4 and CD90.1. Numbers in FACS blots indicate frequencies 
and bar graph shows cell numbers. (B) CD4+ T cells from immunized mice were analyzed for 
CD62L and CD44 expression. Histograms show CD62L and CD44 expression specifically on 
CD4+CD90.1+ cells (OT-II). The data shown in this figure are from one representative experiment 
out of three, which was carried out in triplicates. 
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5.4.3 DC subsets in Cdc42-ko mice differentially regulate Ii 
expression 
We next sought to take a closer look at the spleen and lymph node DC populations 
in Cdc42-ko mice. From our studies using in vitro generated DCs we know that Ii 
accumulates at the cell surface of Cdc42-ko BMDCs, thereby possibly preventing 
peptide exchange. Therefore, we characterized CD11c+MHC II+ spleen DCs with 
respect to Ii surface expression. We made the interesting observation that 
despite of equal MHC II expression at the cell surface of CD8+ and CD8- wt spleen 
DCs, Ii-bound to MHC II (15G4) expression was substantially reduced on CD8+ as 
compared to CD8- DCs (Figure 23A, left and middle panel). The ratio of 15G4 and 
MHC II fluorescence was accordingly much higher in CD8+ spleen DCs isolated 
from wt mice (Figure 23A, right panel, white bars). However, when we 
investigated Cdc42-ko spleen DCs we could detect neither stronger 15G4 
fluorescence, nor an increased ratio on CD8+ and CD8- Cdc42-ko spleen DCs as 
compared to wt cells, indicating that Ii surface expression was not elevated on 
Cdc42-ko spleen DC subsets. Notably, the knockout was not complete in sorted 
Cdc42-ko spleen DCs (Paper I, Supplementary Figure S1D), indicating that there 
might be remaining Cdc42 protein in these cells analyzed. 
In order to characterize other in vivo DC subsets, we analyzed migratory DCs 
(mDCs) and resident DCs (rDCs) from cutaneous draining lymph nodes. Whereas 
the MFI of Ii-bound MHC II (15G4) was normal on both cutaneous lymph node 
DC subsets, the MFI of total MHC II was decreased on Cdc42-ko mDCs 
(Figure 23B, middle panel). Hence we observed an increased Ii surface expression 
relative to total MHC II, as indicated by the ratio MFI 15G4/MHC II (Figure 23B, 
right panel). This observation was interesting, because mDCs from Cdc42-ko mice 
were present at low frequencies and numbers and seem to be severely affected 
upon Cdc42 knockout (Paper I, Figure 1A (gate R2)). 
 
Since mDCs from cutaneous draining lymph nodes cannot be analyzed by 
Western blot due to very low cell numbers, we instead analyzed Ii processing in 
purified MHC II+CD11c+CD8+ and CD8- spleen DCs. Interestingly, CD8+ wt spleen 
DCs showed higher amounts of intracellular Ii and accumulated the smallest p12 
fragment, as compared to CD8- wt spleen DCs (Figure 23C). This differential Ii 
expression pattern in CD8+ vs. CD8- spleen DCs surprisingly does not correlate 
with surface-Ii levels: CD8+ spleen DCs expressed high intracellular Ii and are low 
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in 15G4 epitopes at the cell surface, whereas CD8- spleen DCs show the opposite 
phenotype. At the same time, Ctsl levels were reduced in CD8- DCs. However, 
spleen DCs from Cdc42-ko mice showed both, an accumulation of the smallest p12 
fragment of Ii and a reduced expression of Ctsl protein in both DC subsets 
(Figure 23C), as compared to their wt counterparts, which matches the Ii 
processing pattern observed in Cdc42-ko BMDCs (see Figure 13). 
Taken together, we could confirm a role for Cdc42 in MHC II antigen presentation 
in vivo (Figure 22), but detected normal expression of Ii at the cell surface of 
Cdc42-ko spleen DCs, despite of an altered Ii processing pattern (Figure 23). 
However, mDCs from cutaneous draining lymph nodes showed an increased 
expression of Ii at the cell surface as compared to rDCs, indicating that DC subsets 
from different organs might display altered Ii processing patterns and/or 
turnover rates at the cell surface. 
 
Figure 23:  DC subsets differentially regulate Ii expression. 
(A) Spleen DCs (CD11c+MHC II+) were analyzed for Ii surface expression; CD8 was additionally 
used to discriminate between DC subsets. Bar graph shows the amount of Ii (Ratio MFI 
15G4/MHC II) expressed on CD8+ and CD8- spleen DCs. Data are from one experiment (n=3) out 
of three. (B) Migratory and resident DCs (mDCs and rDCs) in skin-draining lymph nodes were 
analyzed for surface Ii expression. Bar graph shows surface-Ii expression (Ratio MFI 
15G4/MHC II) relative to wt. Data are combined from three independent experiments (n=6). (C) 
Spleen DCs were sorted on a FACSAria instrument based on the expression of CD11c, MHC II and 
CD8. Total cell lysates from CD8+ and CD8- DCs were analyzed by Western blot for Ii degradation 
intermediates and Cathepsin L protein levels. Bar graphs show signals normalized to actin. 
A. 
CD
8
15G4
Spleen:
Ra
tio
 M
FI
 1
5G
4/
M
HC
 II wt
Cdc42-ko
CD8      +     -            +      -
Actin
wt           Cdc42-ko
CD74: p41
p31
p12
C. 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Cathepsin L
CD8+ CD8-
CD74-p12
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
CD8+ CD8-
20kDa Cathepsin L
Re
la
tiv
e 
ex
pr
es
si
on
wt
Cdc42-ko
15G4
wt
Cdc42-ko
MHC II
CD8+
CD8-
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
CD8+ CD8-
B. 
mDCs
rDCs
mDCs
rDCs
15G4 MHC II
M
HC
 II
CD11c
Ra
tio
 M
FI
 1
5G
4/
M
HC
 II
re
l. 
to
 w
t
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
*
**wt
Cdc42-ko
mDCs rDCs
wt
Cdc42-ko
Sorted spleen DCs:
Cutaneous LN:
CD11c+MHC II+ 
DISCUSSION 
 68 
6 DISCUSSION 
6.1 Cdc42 controls DC-mediated immunity 
Silencing of Cdc42 impairs the DC’s potential to take up antigens and delays 
immune responses, which are fundamental DC functions required for effective 
onset of immunity. In brief, we showed that cells deficient for Cdc42 were 
inefficient in antigen uptake, possibly through their inability to re-shape the 
plasma membrane to engulf the antigen. Furthermore, Cdc42-ko DCs not only 
express low levels of MHC I, but also high levels of immature MHC II still 
occupied by Ii at the cell surface and deficiently primed both the CD8+ and CD4+ 
T cell responses. 
DCs are important immune cells, since they are amongst the first cells in contact 
with a pathogen. Upon encounter of bacterial or viral antigens, DCs obtain a 
mature phenotype that fully enables them to induce specific immune responses by 
their interactions with T cells. Interestingly, bacteria as well as viruses have found 
ways to influence the DC’s potential to become fully activated and/or obtain all 
defense mechanisms required for the induction of antigen-specific immune 
responses. As a matter of fact, many of these mechanisms include the regulation of 
Rho GTPase activities by bacterial or viral products. For example, many bacterial 
virulence factors either activate or inactivate the Rho GTPases Rac1, Cdc42 or 
RhoA. One virulence factor that co-activates Rac1 and Cdc42 by its GEF activity is 
the Salmonella protein SopE. SopE-induced over-activation of these Rho GTPases 
causes a massive production of lamellipodia and filopodia around cell edges, 
provoking cell spreading, but inhibiting motility, thereby inducing local bacterial 
cell invasiveness (67).  
 
Interestingly, the viral human immunodeficiency virus (HIV-1) accessory protein 
Nef, produced early after infection, also triggers mechanisms that make cells non-
responsive promoting HIV’s evasion of the cellular immune response:  
First, Nef induces an accelerated internalization of MHC I protein from the plasma 
membrane, resulting in low MHC I surface expression on lymphoid, monocytic 
and epithelial cells (98) and immature PBMC-derived DCs (99). This down-
regulation of MHC I protects the infected cells from cytotoxic T lymphocyte killing 
(100) and delays an immune response. In this study we show that Cdc42-ko 
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BMDCs display a reduced expression of MHC I at the cell surface (Figure 4B and 
C). The reason for this phenotype is unclear and has not fully been uncovered. The 
internalization of MHC I could be one factor leading to reduced MHC I surface 
levels, but was not tested in this study. Instead, we studied intracellular MHC I 
protein expression and found it slightly reduced (Figure 5A). This reduction was, 
however, not statistically significant. It has to be noted here that increasing the 
number of biological replicates for this experiment might confirm this 
downregulation and should be subject of future experiments.  
Second, in human PBMCs the HIV-1 protein Nef induces Vav phosphorylation, 
which leads to an increase of both Rac1 and Cdc42 activities, the latter to a lesser 
extent. Activation of Rac1 by Nef triggered rearrangements of actin filaments, the 
formation of uropods and ruffles and an increase of the DC’s ability to form 
clusters with allogeneic CD4+ T cells (101), fostering virus dissemination though 
activation of these T cells. In cells deficient for Cdc42 we did not investigate the 
amount of activated Rac1. However, it may be noted here that feedback 
mechanisms triggering GEFs that target both Rac1 and Cdc42 (e.g. proto-oncogene 
Vav) could indeed change the expression levels of total and GTP-bound Rac1 in 
the absence of Cdc42 and thus, induce cytoskeletal changes and surface marker 
expression in a Nef-similar fashion as secondary effects of Cdc42 removal. Indeed, 
in our proteomics screen p95vav (Vav1) protein was present at slightly elevated 
amounts in Cdc42-ko BMDCs (mean fold change value (FC) Cdc42-ko/wt±SEM: 
1.4±0.46), and could possibly, in the absence of Cdc42, target Rac1 (FC Cdc42-
ko/wt±SEM: 1.3±0.43) instead. However, an effect of Cdc42-removal on Rac1 
activation can only be speculated and might be unraveled in future experiments. 
Third, another study showed that Nef stabilizes Ii-bound MHC II at the cell 
surface of infected HeLa-CIITA cells, while reducing surface levels of mature, 
peptide-loaded MHC II (102, 103), affecting MHC II function and peptide 
presentation. Ii-bound “immature” MHC II molecules were also stabilized on the 
cell surface of Cdc42-ko BMDCs (Figure 12A and B), due to a decreased 
internalization (Figure 12C). However, although the amount of peptide-loaded 
MHC II was not determined in this study, we observed a low expression of total 
MHC II molecules on immature BMDCs deficient for Cdc42 (Figure 4B and C). 
These studies provide evidence, that studying Cdc42 function in DCs could give 
promising insights in the DC’s exact mechanisms to fight viral transmission. 
Indeed, a study using immature DCs elegantly showed that cell-to-cell 
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transmission of HIV-1 was Cdc42-dependent: DCs silenced for Cdc42 lacked 
membrane protrusions induced by the virus to facilitate the transfer of viral 
particles to CD4+ T cells (104).  
 
The present study aimed at understanding the mechanisms regulated by Cdc42 in 
immature and mature DCs and which influence Cdc42 has on basic DC functions 
such as the presentation of exogenously derived antigens. 
 
Phenotype of Cdc42-ko BMDCs 
Immature Cdc42-ko BMDCs express low levels of MHC I as well as MHC II 
molecules (discussed below) that mediate the presentation of antigens to T cells. 
DC maturation can be induced by LPS treatment, which enables their priming 
ability required for the initiation of immune responses. This process is 
accompanied by substantial rearrangements of the actin cytoskeleton (105), 
leading to a shutdown of endocytosis of soluble antigens and a transport of MHC 
molecules to the cell surface (72). However, Cdc42-ko BMDCs normally 
responded to LPS and were able to upregulate MHC I as well as MHC II cell 
surface expression (Figure 4B and C), indicating that TLR4 signaling was still 
functional. Indeed, it has been reported that Cdc42 activity did not increase in 
BMDCs treated with LPS (106), but rather gradually decreased upon DC 
maturation, as also described by Mellman’s group (72). As a result, Cdc42 activity 
was high in immature DCs resulting in a high potential of endocytosis, and 
downregulated in mature DCs in order to shut down this process. As opposed to 
Mellman’s observations, human LC-type DCs show a different phenotype 
regarding the regulation of Cdc42 activity upon maturation: these human DCs 
treated with LPS did upregulate Cdc42 activity, which resulted in an activated DC 
phenotype (69). The authors claim that active Cdc42 is required for “the 
maintenance of a typical actin cytoskeleton” of mature DCs. This study suggests 
that Cdc42 might be differentially regulated during DC development in DC 
subsets in mice and humans, or different DC subsets.  
In our system unstimulated Cdc42-ko BMDCs lack Cdc42 protein, whereas wt 
BMDCs should, according to Mellman’s observations, express high amounts of 
active Cdc42. This deficiency in unstimulated Cdc42-deficient cells causes 
malfunctions concerning MHC expression, antigen uptake and antigen 
presentation. Upon treatment with LPS these knockout BMDCs became activated 
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and upregulated MHC and costimulatory molecules, indicating that a deficiency 
of Cdc42 in immature DCs does not inhibit the onset of DC maturation. This 
would be in agreement with Mellman’s observations that Cdc42 activity is 
required for basic DC functions such as antigen uptake in immature DCs, and 
downregulated upon maturation. Thus, our results support the notion that Cdc42 
might have prevalent functions in immature DCs. 
 
In addition to a decreased expression of MHC I and MHC II, immature Cdc42-ko 
BMDCs express low levels of CCR7 (Figure 4B). This decrease in CCR7 expression 
on Cdc42-ko BMDCs could indicate a functional relationship between CCR7 
signaling and Cdc42 activation. A recent study in spleen DCs showed that cross-
linking of CCR7 with its ligand CCL19 increased the amount of active, GTP-bound 
Cdc42, which lead to an increased endocytic capacity of these cells (107). Besides 
endocytosis, CCR7 signaling was shown to be important for skin-DC migration to 
draining lymph nodes (108), which is a prerequisite for antigen transport from 
sites of infection to sites of T cell activation. Because of reduced CCR7 surface 
levels, CCR7 signaling might therefore not be functional in DCs deficient for 
Cdc42- with fundamental consequences for the initiation of immune responses 
requiring both functional antigen uptake and its transport. This might be of 
interest for future in vivo-studies with Cdc42-ko mice. 
 
Antigen uptake and processing 
Cdc42 controls the acquisition of soluble antigens, as shown in Figure 6. Our 
results are in agreement with previous studies using BMDCs showing that 
macropinocytosis, receptor-mediated uptake and pinocytosis (71, 72) required 
functional Cdc42 protein. However, a study using spleen DCs challenged the 
concept that these processes are conserved between DC subsets, by showing that 
cultured N17Cdc42-transfected spleen DCs did not show a significant defect in the 
uptake of soluble dextran (109). The authors argued that BMDCs and spleen DC 
populations might differentially express Rho GTPases and/or their effectors, 
which could possibly account for differences in regulation. Therefore, DC subsets 
might use different strategies to regulate endocytosis in response to environmental 
stimuli. Thus, Cdc42 might have altered, extenuated functions in spleen DCs in 
vivo as compared to in vitro generated BMDCs, where the strong GM-CSF stimulus 
might additionally influence DC-functions of GTPase-regulation. Interestingly, 
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our own results also point towards the possibility that endocytosis in DC subsets 
might be differently affected upon Cdc42-knockout. Cdc42-ko CD8+ spleen DCs 
were fully capable of taking up soluble OVA, which was true for both ex vivo (data 
not shown) as well as in vivo OVA uptake (Céline Leroy, personal 
communication). Additionally, LCs isolated from the epidermis of Cdc42-ko mice 
were capable of taking up comparable amounts of OVA protein ex vivo (data not 
shown), suggesting that also LCs might regulate OVA uptake differently, as 
compared to in vitro generated BMDCs. However, to fully address these 
differences and the specific contribution of Cdc42 to endocytosis within different 
(wt-) DC subsets, further studies are required that would ideally correlate antigen 
uptake capacity with protein levels of active, GTP-bound Cdc42. 
 
Interestingly, OVA that was taken up with reduced efficacy was nevertheless 
efficiently degraded by Cdc42-ko BMDCs (Figure 6C). Hence, we could exclude a 
role of Cdc42 in OVA processing. However, given the multiple pathways by 
which OVA protein can be degraded, this finding might not only account for 
proteins that are presented via MHC II and are destined for proteolytic 
degradation in lysosomes. In fact there is emerging evidence that, depending on 
their intrinsic properties, DC subtypes take up soluble antigens via different 
routes that selectively trigger intracellular pathways of peptide generation 
promoting either CD4+ or CD8+ T cell activation. For example, a study showed that 
mannose receptor (MR)-dependent OVA uptake in CD8+ spleen DCs introduced 
OVA into stable early endosomal compartments, from where it entered the cross-
presentation pathway. This pathway also includes protein degradation by the 
proteasome complex, generating peptides that are loaded onto MHC I molecules 
and then presented to CD8+ T cells (110). CD8- DCs, on the other hand, take up 
OVA via pinocytosis and directly conveyed the protein to lysosomes for MHC II-
restricted antigen presentation to CD4+ T cells. Also, OVA targeting with 
antibodies that triggered receptor-mediated uptake in CD8+ (αDEC205-OVA) or 
pinocytosis in CD8- DCs (α33D1-OVA), subjected OVA for presentation to CD8+ or 
CD4+ T cells respectively (111). However, since we did not target a specific route 
of OVA uptake but rather used unconjugated OVA protein, our experimental 
setup did not allow the discrimination between proteasome-dependent and -
independent mechanisms of antigen processing, and thus, only provides 
quantitative rather than qualitative evidence. Furthermore, for both MHC I as well 
DISCUSSION 
 73 
as MHC II antigen presentation, cells possess a variety of proteases with broad 
specificities, as reviewed for the MHC I pathway (31), that might already process 
OVA in Cdc42-ko DCs before it actually reaches lysosomal compartments. To 
improve the experimental setup, a negative control for OVA processing (e.g. 
ConB) could be included that blocks acidification of the endosome and thus, might 
result in attenuated OVA-degradation. Also, antibody-tagged latex beads could 
trigger a specific pathway of entry. 
 
Antigen presentation 
We next studied the functional consequences of Cdc42-depletion in BMDCs for 
T cell priming. Cdc42-ko DCs failed to prime CD8+ as well as CD4+ T cells when 
pulsed with whole protein antigen or pre-processed antigenic peptides (Figure 7). 
While it was expected that reduced antigen uptake might lead to the generation of 
fewer antigenic peptides presented in the context of MHC I and MHC II in Cdc42-
ko DCs (Figure 7A), this defect could interestingly not be overcome by loading 
MHC molecules of activated DCs with pre-processed antigenic peptides 
(Figure 7B). Our results concerning the presentation of whole protein antigen are 
in agreement with previous studies showing that BMDCs deficient for functional 
Cdc42 protein fail to induce proper immune responses to CD4+ T cells, when 
pulsed with whole OVA protein (71). Also, a study using human LC-type DCs 
showed an impaired CD8+ T cell response, after pre-processed OVA peptide was 
applied to the cells (69), which was due to low surface expression of MHC I and 
costimulation on mature DCs deficient for functional Cdc42. 
To overcome a possible inability of Cdc42-ko BMDCs to form functional DC:T cell 
synapses due to cytoskeletal defects possibly caused by the loss of Cdc42, we 
performed the antigen presentation assay in round-bottom plates that, as opposed 
to flat-bottom plates, force DCs and T cells to fall in close proximity to each other 
(93). However, a recent study showed that DCs transfected with Cdc42-siRNA 
were in fact able to form DC:T cell contacts, thereby inducing OT-I cells to enter 
division, which, however, did not accumulate due to reduced T cell survival. 
Rather than being important for DC:T cell contact formation, in DCs Cdc42 was 
shown to mediate the polarization of intracellular stores of IL-12 towards the 
immunological synapse (61); IL-12 release by DCs constitutes a third signal 
promoting full activation and survival of activated T cells. Interestingly, own data 
also showed that IL-12 secretion indeed was significantly reduced upon Cdc42-
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removal (60±7.2 % of wt, n=8, **p<0.001; data not shown), as measured by CBA 
(see 4.2.1.7) on supernatants of LPS-treated Cdc42-ko BMDCs. In this regard, also 
the pro-inflammatory cytokines IL-6 and TNF were highly significant reduced in 
supernatants of LPS-treated Cdc42-ko BMDCs (39±5.8 % and 44±5.4 % of wt 
respectively, n=8, ***p<0.0001; data not shown). These results suggest that in DCs 
lacking Cdc42 multiple pathways including the release of inflammatory cytokines 
might be affected, adding up to their inability to fully activate T cells. 
6.2 Loss of Cdc42 affects actin dynamics and vesicle 
trafficking 
Having identified a function of Cdc42 in cellular processes tightly associated with 
antigen presentation we wondered, which pathways might be affected upon 
Cdc42 knockout that add up to their inability to fully prime T cells. Using 
proteomics we determined changes in the whole proteome composition of DCs 
deficient for Cdc42. We were surprised by the fact that Cdc42 seemed to be a 
rather global player for important DC immune functions. The global analysis of 
up- and downregulated proteins upon Cdc42 removal revealed known 
interactions, but also unknown functions, for example the general involvement of 
Cdc42 in controlling the DC’s lysosomal protein composition (Table 11). Gene 
Onthology (GO) term analysis of proteins grouped according to their molecular 
function, biological process or cellular component was used to reveal novel 
candidates with novel functions of Cdc42 in DCs. As an example, a GO term that 
was substantially affected in Cdc42-ko BMDCs was the molecular function Actin-
binding Proteins (GO:0003779, Table 12). Interestingly, few proteins (Arpc2, Vasp) 
were mentioned as directly associated with Cdc42 function, whereas others 
represent novel candidates that have not been directly associated with Cdc42 
before. For example Palladin (FC 0.002±0.0017), a protein that localized to actin-
containing podosomes of immature human monocyte-derived DCs and along 
actin filaments upon maturation (112), was virtually absent from Cdc42-ko 
BMDCs. Another GO term substantially affected was the Biological Process 
intracellular protein transport (GO:0006886, Table 13), showing also known, and 
novel relationships. However, in order to prove, whether these theoretical changes 
in protein composition are valid, confirmation of data would be required for each 
protein, as we did for selected proteins using biochemical methods like Western 
blot or flow cytometry.  
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6.3 MHC II loading requires Cdc42 and a functional actin 
network  
Having identified a function of Cdc42 in the induction and control of DC-
mediated immune responses, we sought to determine the mechanism, by which 
Cdc42 specifically affects MHC II antigen presentation. Until now, a regulation of 
MHC II expression on the cell surface of DCs has not been connected with Cdc42 
function so far. However, using a literature-based model Paul et al. propose an 
influence of Cdc42 protein on the MHC II pathway via its role for endocytosis of 
exogenous antigens (31). In our study we suggest a previously unknown role for 
Cdc42 in MHC II loading based on three observations: Cdc42-ko BMDCs (i) 
accumulated Ii-bound MHC II at the plasma membrane, (ii) accumulated the 
smallest degradation intermediate of Ii, Ii-p12, intracellular and (iii) expressed low 
levels of the protease Ctss that conducts the final step of Ii-p12 processing. These 
processes contribute to pre-occupied MHC II molecules at the cell surface of 
Cdc42-ko BMDCs, which are not susceptible for loading with antigenic peptides. 
Moreover, we found that these processes were also actin-dependent and conclude 
that Cdc42 might trigger MHC II loading by influencing actin-dynamics. 
 
Accumulation of Ii-bound MHC II at the plasma membrane  
Ii-occupied MHC II heterodimers travel from the ER to MIICs, either directly 
through the endocytic pathway, or indirectly via the plasma membrane and 
subsequent endocytosis. However, in immature DCs only a small fraction of Ii-
occupied MHC II at the plasma membrane is detectable due to fast internalization 
rates. Hence, an unexpected and fundamental finding was that “immature", Ii-pre-
occupied MHC II molecules were stabilized at the plasma membrane of Cdc42-ko 
BMDCs (Figure 12) and actin-inhibitor treated wt BMDCs (Figure 15A and C).  
Trafficking of nonameric Ii-bound MHC II molecules depends on two dileucine-
based sorting motifs integrated in the cytoplasmic part of the Ii chaperone. Ii-
associated MHC II is endocytosed predominantly through the interactions of these 
sorting motifs with the clathrin-adaptor protein AP-2 (113, 114), which is part of 
the clathrin coat required for vesicle budding. An explanation for the stabilization 
of Ii at the plasma membrane of Cdc42-ko BMDCs could be altered cell surface 
dynamics upon the loss of active Cdc42 protein. Interestingly, we could also 
define a contribution of the actin cytoskeleton in the turnover of Ii-bound MHC II, 
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which was stabilized upon global inhibition of actin-polymerization on the cell 
surface of wt cells (Figure 15A). The contributions of Cdc42 on cell surface 
dynamics are multi-facetted, but all of them include actin polymerization as a 
downstream signaling event upon Cdc42 activation (reviewed in (51)). In this 
regard, clathrin-mediated vesicle budding at the plasma membrane is Arp2/3- 
and actin-dependent and could be impaired in the absence of Cdc42 despite a 
functional interaction of the Ii cytoplasmic tail with adaptor protein AP-2.  
Cdc42-ko BMDCs also showed a reduced internalization, hence stabilization of 
total MHC II molecules at the cell surface (data not shown). A study showed that 
quick internalization of mature CLIP- or peptide-loaded MHC II molecules from 
the plasma membrane in immature DCs depended on oligoubiquitination of the 
MHC II β-chain, which was, however, suppressed in LPS-activated, mature DCs, 
triggering MHC II stabilization at the cell surface. Interestingly, ubiquitination of 
MHC II-β was dependent on Ii processing: quick internalization of ubiquitinated 
MHC II proteins and targeting to multi vesicular bodies (MVBs) was only 
observed after Ii was fully processed by lysosomal proteases (19). Thus, in Cdc42-
ko BMDCs Ii-p12, which might not have been fully processed into CLIP, may 
prevent the premature exposure of MHC II-β to the ubiquitination machinery, 
thereby stabilizing MHC II at the cell surface in a maturation-independent 
manner. This finding somehow contradicts the low expression of MHC II 
observed at the cell surface of immature Cdc42-ko BMDCs and indicates that a 
certain proportion of MHC II molecules might be retained in intracellular 
compartments of the cell, when Cdc42 is not functional. However, also actin 
inhibition in wt BMDCs by CytD lead to a decreased internalization of MHC II 
(data not shown), indicating that both Cdc42 and functional actin dynamics are 
important for the internalization of MHC II from the plasma membrane.  
 
Intracellular accumulation of Ii-p12 
Intracellular Ii-p12 processing in DCs depends on the protease Ctss (37, 38). 
However, in some cell types, e.g. cTECs, the structurally very similar protease Ctsl 
is the enzyme that conducts this final step of Ii processing (35). Accumulation of 
CLIP- or Ii-p12-bound MHC II at the cell surface has been reported for HIV-
infected HeLa-CIITA cells (discussed above), Ctsl-deficient cortical thymic 
epithelial cells (cTEC) (35), Ctss and Ctsl-deficient fibroblasts using clone 15G4 
antibody (39), Ctss-deficient murine intestinal epithelial cells (IEC) using clone 
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15G4 (40) and H2-M-deficient lymph node cells using clone 15G4 (36); a 
phenotype that was accompanied with an intracellular Ii-p12 degradation arrest in 
these knockout cells. Indeed, the loss of Cdc42 protein and the inhibition of actin 
in DCs both resulted in an accumulation of the smallest, Ii-p12 processing 
intermediate (Figure 15B), possibly as a direct consequence of the absence of Ctss, 
as also described for Ctss-deficient DCs (37, 38). However, even though 
intracellular Ii-p12 accumulation correlated with Ii-stabilization on the cell surface 
of Cdc42-ko BMDCs, the latter might not be a direct consequence of defective Ii 
processing, but rather a secondary effect caused by the inhibition of actin 
dynamics by Cdc42.   
 
Both Cdc42-ko BMDCs and wt BMDCs treated with the actin-inhibitors CytD or 
LatB expressed low intracellular levels of Ctss (Figure 11A and Figure 15B, 
respectively). Consistent with the finding that Ctss was lost from cells treated with 
actin inhibitors, CytD and LatB treated cells accumulated Ii-p12 intracellularly 
(Figure 15B), which was possibly due to poorly equipped late endosomes, where Ii 
processing into CLIP occurs. These results clearly point towards a contribution of 
the actin cytoskeleton in Ii processing. Interestingly, our results are in agreement 
with a study showing that CytD-treated B cells accumulated Ii-p12 intracellular 
(115). However, this study did not address a role of actin dynamics in Ctss 
expression, but rather showed that CytD interfered with MHC II targeting to 
lysosomes, thereby blocking the access of Ii to lysosomal proteases. 
Ii expression at the cell surface was, however, neither microtubule-, nor Arp2/3 
and clathrin-dependent (Figure 15B and data not shown), indicating that 
inhibition of neither of these processes was sufficient to cause this severe 
phenotype. Notably, ConB-treatment also caused a slight but significant 
accumulation of Ii-p12 in inhibitor-treated wt BMDCs (Figure 15B). ConB delays 
endosomal and phagosomal acidification (77) by inhibition of V-ATPase, which 
could possibly result in reduced Ctss activity at high pH. However, Ctss, as 
opposed to most endosomal hydrolases, has been shown to survive and maintain 
enzymatic activity at even a slightly basal pH (116) with approximately 25 % 
remaining activity at pH 7.0-8.0 (117), indicating that a pH above 8.0 might be 
required to fully suppress its activity. Taken together we could define a 
microtubule-independent role of actin dynamics in Ii processing through the 
regulation of lysosomal Ctss levels. 
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Regulation of lysosomal protein contents 
Besides the lack of Ctss, Cdc42-ko BMDCs expressed low levels of many other 
lysosomal proteins (Figure 10 and Figure 11). Interestingly, these changes 
comprised lysosomal membrane proteins as well as soluble proteins; both protein 
groups require different modes of vesicle transport to reach their final destination, 
the lysosome. For example, one of the most abundant lysosomal membrane 
proteins is LAMP-1, which was virtually absent in Cdc42-ko BMDCs, is 
transported in an M6pr-independent manner in AP1+clathrin+ vesicles positive for 
AP1 and clathrin. Cathepsins on the other hand, which are soluble proteases also 
reduced upon Cdc42 knockout, require both M6pr and clathrin to enter the 
endocytic system. Cdc42-ko cells did not accumulate cathepsin precursors, neither 
intracellular nor extracellular, as shown for Ctsd in M6pr-deficient mouse 
embryonic fibroblasts (MEF) (41). This supports the theory that in Cdc42-deficient 
DCs lysosomal proteases might be able to enter the endocytic system 
independently of Cdc42, and are processed into their mature forms. Thus, rather 
than playing a role in the delivery of selected proteins to the lysosome, Cdc42 
seemed to affect a general mechanism leading to the loss of lysosomal proteins 
from cells.  
But which mechanism might cause this phenotype? Besides entering the 
endosomal pathway directly, a small fraction of lysosomal proteases is first 
transported to the plasma membrane and than re-internalized- a pathway of 
minor importance in wt cells. This secretion-recapture pathway is sensitive to 
mannose-6-phosphate in the medium, hence M6pr dependent. Two types of M6pr 
are ubiquitously expressed: a 46 kDa cation-dependent (CD-M6pr) and a 300 kDa 
cation-independent (CI-M6pr, Igf2r) receptor. Both function in transport of 
lysosomal proteases from the TGN and the plasma membrane to lysosomes (27). 
Fibroblasts deficient for both mannose-phosphate receptors (MPR64/CD-M6pr 
and MPR300/Igf2r) missorted the majority (≥ 85 %) of lysosomal proteins into 
culture supernatants (41). Both mannose receptors were expressed at slightly 
elevated amounts in Cdc42-ko BMDCs (FC (Igf2r) Cdc42-ko/wt 25.8±24.14; FC 
(CD-M6pr) Cdc42-ko/wt 4.4±1.91), indicating that the machinery at both the TGN 
and the plasma membrane might be able to “use” these important sorting 
receptors. However, whether the receptors were efficiently internalized from the 
plasma membrane in the absence of Cdc42 was not assessed in this study. 
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To study protease secretion from cells into culture supernatants, we used Ctsl as 
an example lysosomal protein since this enzyme was highly expressed in BMDCs 
and thus, well detectable. Taken both intracellular and extracellular Ctsl 
expression into account, Cdc42-ko BMDCs secreted approximately three fold more 
mature Ctsl protein than their wt counterparts (Figure 17B) irrespective of its 
stability in the medium. Interestingly, actin-inhibition (Figure 17A) and more 
specifically, inbibition of the Arp2/3 complex (Figure 19C) and clathrin (Figure 20) 
in wt BMDCs also resulted in enhanced secretion of mature 20kDa Ctsl protein, 
but not its 37kDa precursor. This result suggests that the pro-enzyme entered the 
endocytic system, matured upon acidification of the vesicle, and was possibly 
finally secreted from a late endocytic compartment upon inhibitor-treatment. 
Consistent with this conclusion was also the preliminary finding that CytD and 
LatB actin-inhibitor treated wt BMDCs lost their lysosomal contents, as measured 
by Lysotracker staining, which is a probe that accumulates in vesicles with low pH 
(data not shown). However, Lysotracker staining was normal in Cdc42-ko BMDCs 
as compared to wt cells as measured from MFI (data not shown), indicating that 
DCs devoid of Cdc42 still expressed acidic, albeit possibly not fully functional 
lysosomes. It has to be noted here that Lysotracker staining examined by flow 
cytometry measures lysosomal contents in quantitative rather than qualitative 
terms. Therefore, future experiments are needed to characterize Lysotracker+ 
vesicles in terms of pH, size and/or distribution within Cdc42-ko cells.  
 
Actin-dynamics are important for both short-range transport and the recently 
discovered collective vesicle movement, which depends on the actin-nucleating 
factors Spire-1, Spire-2 and Formin-2 (64). In brief, short filaments surround the 
vesicle surface, thereby facilitating a connection of the vesicle with the pre-existing 
actin network, inducing its long-range transport via the actin lattice. Interestingly, 
both inhibition of Formin-2 and inhibition of actin by CytD in mouse oocytes 
utilized in this study (64) lead to the loss of both transport directionality and 
vesicle speed, and therefore, drastically decreased actin-dependent vesicle 
transport. Interestingly, the treatment of mouse oocytes with an Arp2/3 inhibitor 
only slightly interfered with vesicle dynamics, indicating that mostly linear, 
formin-mediated actin polymerization played a role for this mechanism of vesicle 
movement along the actin cytoskeleton. Interestingly, not only vesicle speed was 
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affected upon CytD-treatment, but also vesicle convergence (vesicle movement 
towards neighboring vesicles), which increased the number of vesicles per cell 
while their average size significantly decreased (64).  
In wt BMDCs, only the inhibition of Arp2/3, but not the inhibition of formins lead 
to an accelerated Ctsl translocation into supernatants (Figure 19B), indicating that 
specifically actin-branching played a role for Ctsl transport. In addition both 
vesicle convergence and localization could be affected in the absence of functional 
actin dynamics and upon Cdc42 knockout, and impaired Arp2/3 and formin-
signaling could result in smaller lysosomes of higher abundance that cannot 
release their contents due to their inability to fuse with MIICs.  
 
The inhibitor Pitstop 2 is a recently published small molecule that, based on its 
interaction with the amino terminal domain of clathrin heavy chain, was thought 
to inhibit specifically clathrin-mediated endocytosis, while leaving clathrin-
independent endocytosis intact (82). Clathrin-mediated endocytosis occurs at the 
plasma membrane, when specific cargo or transmembrane proteins are 
endocytosed in a clathrin-dependent manner. However, another area of clathrin-
dependent vesicle budding is the TGN, where AP-1 and GGA proteins maintain 
bidirectional traffic between TGN and endosomes (118, 119). Therefore, it was to 
be expected that Pitstop 2 also inhibited clathrin-dependent movement at the TGN 
and therefore the supply of endosomes with protease precursors. Wt BMDCs 
treated with Pitstop 2 showed an accumulation of Ctsl in supernatants (Figure 20). 
However, this phenotype was neither accompanied with a loss of lysosomal 
contents from total cell lysates, nor a defect in MHC II loading, hence constitutes a 
rather mild phenotype as compared to the amounts secreted upon direct actin 
inhibition or knockout of Cdc42. This result might point towards a contribution of 
clathrin to protease secretion, but interestingly, the specificity of Pitstop 2 has 
recently been challenged. As discussed by Lemmon and Traub (120), its mode of 
action could not clearly be defined, since clathrin coated vesicles still budded from 
the plasma membrane. However, these vesicles were not efficiently transported to 
the interior of the cells, so simply seemed to be stabilized and less dynamic (82). 
Furthermore, Pitstop 2 was shown to not only inhibit clathrin-mediated 
endocytosis, but also clathrin-independent endocytosis of the transmembrane 
protein MHC I (121). Therefore, it is currently unresolved whether the inhibitor, 
even though it binds specifically to the clathrin terminal domain, might also bind 
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to a second site of action and hence, might lack specificity. Thus, our effects 
observed upon Pitstop 2 treatment might not be caused specifically by the 
inhibition of clathrin. Future research will be of importance to clearly identify 
underlying mechanism of Pitstop 2 treatment. 
 
The contribution of Cdc42 to clathrin-mediated endocytosis is unclear. We 
examined the expression of Hip1r, a clathrin-coat component that connects 
emerging vesicles to pre-existing actin filaments and found it slightly upregulated 
in Cdc42-ko BMDCs (Figure 21B). However, which effect this overexpression 
might have on clathrin vesicle budding at the TGN can only be speculated. 
Interestingly, a study in HeLa cells showed that Hip1r was present at CCVs 
emerging on the TGN in vesicles positive for M6pr and the Arp2/3 complex (122). 
Furthermore, silencing of Hip1r resulted in Golgi disruption, stabilization of actin 
structures associated with CCVs and impaired Cathepsin D exit from the TGN. 
The authors suggested that Hip1r might negatively regulate actin polymerization 
at the TGN, thereby facilitating the release of CCVs from the TGN (122). Therefore 
we could speculate that in DCs Hip1r-expression could be negatively regulated by 
Cdc42, in order to promote (Arp2/3-dependent) actin polymerization at the TGN, 
required for efficient vesicle release and subsequent vesicle movement. However, 
this effect might be DC-specific since silencing of Cdc42 using the drug Secramine 
A did not arrest pit formation of apical or basolateral pits in polarized epithelial 
cells (123). 
6.4 In vivo DC subsets differentially regulate MHC II 
loading 
The examination of in vivo DC subsets uncovered that Ii processing and thus 
MHC II loading might be differentially regulated in DC subsets. This observation 
is not surprising given the fact that DC subsets differentially express MHC II at the 
cell surface and also show preferences for one or another mechanism of antigen 
presentation. As already introduced in chapter 6.1 DCs display different 
specifications regarding MHC I or MHC II antigen presentation (favored by e.g. 
CD8+ and CD8- spleen DCs, respectively (124)). Interestingly, despite of 
comparable MHC II expression at the cell surface of CD8+ and CD8- DCs, these 
two spleen DC subsets expressed Ii-bound to MHC II (Figure 23A) at different 
amounts: CD8+ DCs displayed less Ii-bound MHC II molecules at the cell surface 
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as compared to CD8- DCs. This is surprising given their preferences for MHC I or 
MHC II antigen presentation (124). One would think that DCs that express high 
level of Ii at the cell surface would be inferior at MHC II antigen presentation as 
compared to DCs expressing high amounts of peptide-loaded MHC II molecules, 
but this reasoning might not to be true for every DC subset. Apparently, the 
quality of MHC II loading is also regulated by factors other than Ii processing; the 
best example are CD8- spleen DCs as very good MHC II presenters despite of their 
high expression of Ii-bound MHC II molecules at the cell surface (Figure 23A, left 
panel). How Cdc42 might be regulated in CD8+ vs. CD8- spleen DCs has not been 
studied so far, but the specialization of endocytosing different kinds of antigens 
points towards a differential regulation of Cdc42 activity in these two DC subsets. 
However, we did not observe a difference regarding Ii expression on Cdc42-ko 
spleen DCs (Figure 23A, right panel) as we see in BMDCs (Figure 12A and B), 
which can be interpreted in different ways. Cdc42-ko spleen DCs are devoid of 
functional Cdc42 message, but express low amounts of residual Cdc42 protein 
(Paper I, Supplementary Figure S1D). Thus, the knockout was not as efficient as 
observed for BMDCs (Figure 3B, right panel). An explanation might be the 
relatively short 3-day lifespan of spleen DCs (125), which could simply be too 
short to degrade 100 % of the remaining Cdc42 protein (half-life of Cdc42 protein 
is approximately 15 h in macrophages (126)). Thus, the attenuated phenotype of 
Cdc42-ko spleen DCs, as compared to BMDCs, could be due to either remaining 
Cdc42 activity in this in vivo DC subset or differential regulation of Cdc42 activity 
by other, subset-specific factors. 
 
DC subsets affected most upon Cdc42 depletion are migratory DCs of all kinds, 
mostly the ones found in cutaneous (Paper I, Figure 1A) or mesenteric (Paper I, 
Figure 2C and D) lymph nodes of Cdc42-ko mice. Also, in absence of 
inflammation spontaneously migrated LCs can be found in reduced numbers in 
the dermis of Cdc42-ko mice (Paper I, Figure 1C). We investigated Ii expression on 
MHC IIHI CD11cIM migratory DCs in cutaneous lymph nodes of Cdc42-ko mice and 
found a significantly increased ratio of Ii expression on MHC II molecules 
(Figure 23B, right panel), indicating that these highly affected DCs might regulate 
Cdc42 similar to our BMDC model, or might as well be completely devoid of any 
residual Cdc42 protein. However, due to technical constraints such as very low 
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DC numbers in cutaneous lymph nodes we were not able to study either Cdc42 
protein expression, or Ii processing by Western blot in this migratory DC subset.  
 
We were, however, able to study Ii processing in spleen DCs and made the 
interesting observation that CD8- wt DCs, showing low CD74 expression as 
compared to CD8+ wt DCs, seemed to process Ii more efficiently than their CD8+ 
counterparts (Figure 23C, left panel, see wt only). In Cdc42-ko spleen DCs both the 
CD8+ and the CD8- DC subset showed an Ii-p12 degradation arrest as compared to 
wt cells. This result was consistent to what we observed in Cdc42-ko BMDCs 
(Figure 13), indicating that Cdc42 might, also in spleen DCs, regulate some aspects 
of MHC II loading. Why inefficient intracellular processing of Ii-p12 did not 
correlate with an increased surface expression of Ii-occupied MHC II molecules on 
Cdc42-ko spleen DCs can only be speculated. Cdc42 might simply be still 
expressed at low amounts sufficient to mediate efficient turnover of cell surface 
proteins, or might account for a partial defect on secretion vs. lysosomal loading.  
Interestingly, spleen DCs of Cdc42-ko mice were not able to fully activate OT-II 
cells, as judged from the reduced downregulation of CD62L on those T cells 
(Figure 22B). As a result, Cdc42-ko spleen DCs could not promote sufficient 
stimulation to induce proliferation in vivo, as observed upon P323-339 peptide 
transfer (Figure 22A). Since we could not control the quality of MHC II peptide 
loading, but have to assume that similar amounts of peptides can be loaded onto 
MHC II molecules on Cdc42-ko spleen DCs (due to similar surface MHC II and Ii 
expression, Figure 23A), there might also other factors account for this phenotype. 
These factors might include DC polarization, the secretion of pro-inflammatory 
cytokines and/or poor DC migration within the spleen after LPS-treatment and 
could be subject of future studies.   
6.5 Conclusion & Outlook 
In this study we wanted to address the role of Cdc42 in DC-mediated immunity 
and, more specific, its contribution to MHC II-restricted antigen presentation.  
We could show that Cdc42 controls fundamental aspects of DC biology such as the 
surface expression of MHC molecules, antigen acquisition and antigen 
presentation. We used a conditional knockout lacking Cdc42 in DCs only, leaving 
other Rho GTPases in DCs and other cell types in the mouse unaffected. Using 
in vitro-generated DCs from these mice we not only confirmed previous studies 
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regarding Cdc42 functions, but also propose a novel Cdc42 and actin-dependent 
mechanism for MHC II loading in DCs. Furthermore, in Cdc42-ko mice we 
uncovered a contribution of Cdc42 to the MHC II-mediated antigen presentation 
and T cell priming functions of DCs using pre-processed antigenic peptide in vivo.  
This study contributes to our understanding of the complicated process of MHC II 
antigen presentation, which is relevant for effective immune responses towards 
extracellular antigens and thus, the induction of adaptive immune responses. Our 
findings help to fully unravel this process. Infection models for viral or bacterial 
diseases may uncover a role of Cdc42 in infected DCs for pathogen recognition 
and clearance. This knowledge could reveal therapeutic strategies to modulate DC 
function in order to support an effective pathogen clearance in DC-mediated 
immunity and could contribute to vaccine improvement.  
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7 APPENDIX 
7.1 Gene Ontology (GO) term analyses 
Table 11: GO analysis CC Lysosome (GO:0005764, 82 of 232 proteins detected) 
Proteins are grouped according to their degree of up- and downregulation in Cdc42-ko BMDCs as 
compared to wt cells. Within these groups, proteins are listed in alphabetical order. As an example, 
a fold change value of 0.007 for Acp5 (first row) indicates that only 0.7 % of this protein was 
detectable in Cdc42-ko BMDCs, as compared to Acp5 protein expression in wt cells. 
Gene name UniProt Fold change (Cdc42-ko/wt) Stabw SEM 
  > 3 fold downregulated   
Acp5 Q05117 0.007 0.007 0.005 
Asah1 Q9WV54 0.150 0.084 0.060 
Ctsb P00787 0.237 0.233 0.165 
Ctsl P07154 0.173 0.157 0.111 
Dnase2a P56542 0.092 0.009 0.006 
Lamp1 P11279 0.144 0.135 0.096 
Lipa Q64194 0.207 0.066 0.047 
Man2b1 O09159 0.272 0.063 0.044 
Tpcn1 Q9ULQ1 0.122 0.166 0.117 
  > 2 fold downregulated   
Acp2 P11117 0.490 0.133 0.094 
Ctsd P24268 0.416 0.527 0.372 
Ctsz Q9WUU7 0.490 0.134 0.094 
Fnbp1 Q80TY0 0.368 0.107 0.076 
Ggh Q9Z0L8 0.368 0.047 0.033 
Glb1 P23780 0.408 0.129 0.091 
Gm2a Q60648 0.352 0.223 0.157 
Manba Q8K2I4 0.442 0.112 0.079 
Npc2 P61916 0.406 0.112 0.079 
Plbd2 Q3TCN2 0.495 0.153 0.108 
Tpp1 O14773 0.354 0.054 0.038 
  between 2 fold down- and upregulated   
Ada P00813 0.525 0.443 0.313 
Arl8a Q8VEH3 0.520 0.146 0.103 
Arl8b Q9CQW2 1.359 0.726 0.513 
Arsa P50428 0.785 0.096 0.068 
Cat P04762 1.497 0.228 0.161 
Cst3 P14841 1.493 1.229 0.869 
Ctsa P16675 0.559 0.103 0.073 
Ctsc P80067 0.736 0.170 0.120 
Ctss O70370 0.633 0.191 0.135 
Galns Q571E4 1.314 0.036 0.025 
Gba Q69ZF3 0.626 0.086 0.061 
Gla P06280 0.726 0.345 0.244 
Gns Q8BFR4 0.629 0.600 0.424 
Got1 P13221 0.580 0.114 0.081 
Gusb P06760 0.951 0.130 0.092 
The table continues on the next page. 
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Gene name UniProt Fold change (Cdc42-ko/wt) Stabw SEM 
  between 2 fold down- and upregulated   
H2-Aa P14434 0.950 0.364 0.258 
H2-DMa P28078 1.799 0.712 0.504 
H2-Eb1 P01911 1.504 0.284 0.201 
Hexb P20060 0.508 0.073 0.052 
Ifi30 P13284 1.877 0.028 0.020 
Il4i1 O09046 1.311 1.208 0.854 
Lamp2 P13473 0.529 0.335 0.237 
Mtor P42345 1.109 0.635 0.449 
Naaa Q9D7V9 0.833 0.332 0.235 
Naga Q9QWR8 1.573 0.067 0.047 
Ncstn P57716 1.655 0.814 0.576 
Npc1 O35604 0.829 1.161 0.821 
Pcyox1 Q9UHG3 1.869 1.587 1.122 
Pla2g15 Q8VEB4 1.562 1.946 1.376 
Pon2 Q62086 0.837 0.866 0.612 
Ppt1 P50897 1.519 0.399 0.282 
Prcp Q7TMR0 0.733 0.058 0.041 
Prdx6 O08709 0.971 0.012 0.009 
Psap P07602 1.827 2.087 1.476 
Rab14 P61107 1.164 0.466 0.330 
Rab7 P51149 1.554 0.435 0.307 
Rab9 P51151 1.288 1.293 0.914 
Rraga Q7L523 0.897 0.516 0.365 
Rragc Q9HB90 1.221 0.905 0.640 
Snap23 O00161 0.783 0.103 0.073 
Stx7 O70257 0.646 0.025 0.018 
Stxbp2 Q15833 1.211 0.496 0.351 
Vps36 Q91XD6 1.581 0.186 0.132 
Vps4b O75351 1.237 0.028 0.020 
  > 2 fold upregulated   
Adam8 P78325 2.547 2.514 1.778 
Sphk2 Q9JIA7 2.105 0.463 0.327 
Stx8 O88983 2.528 0.398 0.282 
Unc13d Q70J99 2.364 0.149 0.106 
Vamp7 Q9JHW5 2.551 1.608 1.137 
Vps39 Q8R5L3 2.867 2.548 1.802 
  > 3 fold upregulated   
Anxa11 P50995 3.521 0.724 0.512 
Ass1 P09034 5.692 1.375 0.973 
Fuca1 P17164 54.831 1.280 0.905 
Igf2r Q07113 25.807 34.145 24.144 
Kif2a P28740 3.788 3.298 2.332 
Lrba Q9ESE1 4.983 0.965 0.682 
M6pr P24668 4.411 2.705 1.913 
Rab27a P51159 3.708 0.322 0.227 
Tm9sf1 Q9DBU0 4.310 4.493 3.177 
Vps11 Q91W86 3.375 3.377 2.388 
Vps18 Q8R307 4.083 3.648 2.580 
Vps33b Q9H267 3.845 3.950 2.793 
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